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Copper complexes have been reported to have anti-inflammatory activities for the alleviation of 
inflammation associated with rheumatoid arthritis (RA).   The present study focuses on the 
design of new drugs that could be used to change the bioavailability of copper and hence 
alleviate inflammation.   The ligands chosen were sarcosyl-L-histidyl-L-lysine, sarcosyl-L-
lysyl-L-histidine, sarcosyl-L-histidyl-L-histidine, sarcosyl-L-lysyl-L-lysine and sarcosyl-L-
glycyl-L-histidine.   Equilibrium constants of H+, Cu(II), Ni(II) and Zn(II) with the peptides 
were measured in aqueous solution at 25±0.01oC and an ionic strength of 0.15M (NaCl) using 
glass electrode potentiometry.    The tripeptides species showed significantly different 
coordination behaviour.   The results that Cu(II) coordinates to one amino group, two 
deprotonated peptides and one imidazole nitrogen atoms to give a neutral complex.    
 
The structures of the complex species were investigated using ultraviolet-visible (Uv-Vis), 
nuclear magnetic resonance (NMR), electrospray ionisation mass spectrometry (ESI-MS) 
spectroscopy as well as molecular mechanics (MM) calculations.   The visible spectra obtained 
for the different species in solution were typical of Cu(II) and Ni(II) complexes.      1H NMR 
identified the active binding sites to be the imidazole nitrogen, the amide nitrogen and the 
terminal amino group.   The imidazole nitrogen was involved in coordination first, followed by 
the amide and then the terminal amine groups.   The ԑ-amino group of lysine did not coordinate 
to the Cu(II).    Molecular mechanics was used to support the Cu(II) structures postulated from 
potentiometric and spectroscopic data.    
 
The prefered method of increasing the available pool of low molecular weight Cu(II) species in 
vivo is via dermal absorption.   For this reason the drugs were designed so that they could be 
administered dermally and be selective for Cu(II) so that they do not affect the speciation of 
other metal ions in blood plasma.   Speciation calculations of Cu(II) using a computer model of 
blood plasma indicated that Sar-Lys-His was the best at mobilising copper in vivo. 
 
This study also considered percutaneous skin absorption.   Octanol/water partition coefficients 
and Franz cell permeation studies showed that the Cu(II) complexes are hydrophilic but that 
Sar-Gly-His caused a 2 fold increase in membrane permeability of Cu(II).  
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Rheumatoid arthritis (RA) is an autoimmune disorder characterized by systemic, erosive 
synovitis, and extra-articular involvement.   It may result in nearly complete functional 
defect, lead to chronic pain and also cause chronic inflammation of the joints [1,2].   The 
cause of RA is not yet known, but the symptoms include morning stiffness, non-specific 
joint pains, swelling and tenderness around inflamed joints, and loss of functioning and 
mobility of joints [3,4].   The joints usually in the hands, wrists, knees or feet, on both 
sides of the body swell and become painful, tender and stiff.   A typical RA joint is 
shown in Figure 1.1. 
 
 
Figure 1.1: Normal, healthy joint and a joint affected by Rheumatoid Arthritis. 
 
Furthermore, acute and chronic inflammation is characterized by changes in the 
metabolism of copper [5,6].  
Previous studies have shown that RA patients have increased levels of copper in their 
blood plasma [7,8].   One view is that the rise in total serum copper measured in 
inflammation is held to represent the natural anti-inflammatory (AI) response of the 
organism itself.   The responsiveness of inflammatory disorders to copper 
supplementation suggests that the control exerted by endogenous copper on 
inflammation be susceptible to enhance by exogenous sources. When copper complexes 





were administered subcutaneously, the reduction in inflammation was proportional to 
the total amount of copper injected [9].   However, the precise mechanism by which this 
is achieved has not yet been established.   Copper bracelets are reported to reduce the 
inflammation associated with rheumatoid arthritis.     It is believed that sweat transports 
copper through the skin to its target site.   Pharmacological evidence suggests that 
copper complexes can be beneficial in alleviation and treatment of RA and that these 
compounds have disease remitting qualities [10,11].   Unbound (free) copper is not 
found in large amounts in the human body.   Instead, almost all copper is bound to either 
the storage proteins (metallothioneins), the transport proteins (ceruloplasmin and serum 
albumin), or copper-containing enzymes [12].  
 
Copper complexes almost always have stronger activity than their parent compounds or 
ligands.   It has been hypothesized that the active form of a number of general anti-
inflammatory drugs are their copper complexes.   The sum of this research has 
demonstrated that the copper complexes of most of the anti-inflammatory compounds, 
as well as of many other compounds, possess strong anti-inflammatory activity in 
various models of inflammation. In addition, these copper complexes have been found to 
exhibit lower toxicity as well as higher anti-inflammatory activity as compared to their 
parent compounds or ligands [13].  
 
1.2 Copper Complexes as Anti-Inflammatory 
Copper exists as a metal in the oxidation states (0), (I), (II) and unstable (III), but as 
Cu(II) ion in aqueous solution [14].  
Copper is an essential trace element that acts as a cofactor for a variety of enzymes by 
virtue of its ability to accept and donate electrons under physiological conditions.   The 
copper content and ceruloplasmin activity of serum are significantly elevated above 
normal values in inflammatory diseases in both human and animals.   The copper in 
widely different chemical forms is used as a therapeutic agent in therapy for chronic and 
acute inflammation [15].  
The most popular medications used in such situations are the non-steroidal anti-
inflammatory drugs, generally known by the acronym NSAIDs, such as local 
anaesthetics, opioids, N-methyl D-aspartate (NMDA) receptor antagonists, aspirin, 
ibuprofen etc.   These have been found to be effective in controlling pain.   Opioids and 





NSAIDs are the central analgesics in animal practice [16]. Copper chelation of the 
parent NSAID (such as indomethacin) produces a unique pharmacological substance 
with significantly increased anti-inflammatory potency, broader inhibition of 
inflammatory reactions, and virtual elimination of adverse side effects, especially 
gastrointestinal ulceration.   The Cu-Algesic (it is copper indomethacin 40mg/g) is 
indicated for conditions requiring a potent anti-inflammatory action with excellent 
analgesia, and with reduction of side-effects usually associated with long-term use of 
other NSAIDs.   It is also used in treatment of acute and sub-acute musculoskeletal/ 
locomotor inflammatory conditions in horses [17].  
Most of the ingested copper is excreted via the bile, the major excretory route, thus 
preventing tissue toxicity.   Trace amounts of copper are excreted via urine except in 
cases of copper overload.   Excess copper in the tissue leads to the production of 
damaging free radicals and subsequent DNA cleavage [18].  
In blood plasma, at least 90% of copper is irreversibly bound to ceruloplasmin in a non-
exchangeable form, while about 10% is reversibly bound to serum albumin and less than 
1% is distributed amongst low molecular weight (l.m.w) complexes, predominantly 
[Cu(histidinate)(cystinate)] as the exchangeable copper fraction in the blood [18,19].   
Serum albumin (SA) has been considered to facilitate the transport of trace metals between 
tissues and blood and it is a major metal-binding protein in the body, with about 40 μg of 
copper able to bind to the albumin contained in 1ml of human plasma.   Albumin appears to 
be the primary copper carrier protein in the body [20,21].   It has been observed that serum 
levels of copper are significantly increased during acute phases of RA inflammation, 
returning to normal with remission.   This rise in serum copper is due to an increase in 
ceruloplasmin concentration and represents a physiological response to inflammation.   It 
has, however, been shown that ceruloplasmin is a powerful antioxidant and could thus 
provide protection against cellular destruction [14].   
The role of copper in rheumatoid arthritis (RA) appears to be firmly established [22-27].   
Irrespective of this contradiction, copper complexes were successfully used from the 1940's 
to 1970's in the treatment of various conditions characterized by arthritic changes and 
inflammation [28,29].   However, the development of steroids and aspirin-like non-steroidal 
anti-inflammatory drugs (NSAIDs) quickly replaced copper compounds in the treatment of 
such conditions.   Several researchers have examined the contradictory role of copper in the 
process of inflammation, and they have determined that the enhancement in serum copper is 





a physiological response to inflammation, rather than a cause [30].   In conjunction , the 
main copper-containing enzyme, ceruloplasmin, is significantly increased in inflammatory 
conditions and has anti-inflammatory activity [31].   In addition, it has been found that 
copper deficiency enhances the severity of experimentally induced inflammation [32] and 
that the dietary copper must be enhanced to maintain adequate copper status of animals in 
an inflammatory state [33].  
 
1.3 Literature Review 
Franco and Velo [34] demonstrated that the copper complexes reduce gastric damage 
caused by acetylsalicylic acid (ASA) in animal studies.   Chemical interaction of copper (II) 
with non-steroidal anti-inflammatory agents (NSAIDs) including acetylsalicylic acid (ASA) 
and related substances has been studied in detail by Brumas et al [35].   A relationship 
between copper deficiency and anti-inflammatory (AI) activity of ASA has been           
described [36].  
Fiabane [37] investigated various metal complexes involved in rheumatoid arthritis.   The   
drug-serum albumin copper(II) interactions have been investigated using visible 
spectrophotometry.   In studies on the release of copper(II) from bovine serum albumin it 
was found that the release might occur by a direct complexing mechanism or through a 
remote mechanism involving the drug-copper binding, facilitating the copper release by 
allosteric effects.   Indomethacin, naproxen, ketoprofen, and fenoprofen released copper 
ions remotely to a low molecular weight pharmacoactive form. Acetylsalicylic acid (ASA) 
and D-pencillamine had different modes of action.   Copper supplementation is desirable 
during rheumatoid arthritis treatment with these drugs.   Jackson [38] carried out computer 
simulation study of low-molecular-weight metal complexes involved in rheumatoid 
arthritis.   Sorenson and Jackson et al [19,20] have shown that Cu(II) complexes are 
effective in reducing the inflammation associated with RA, enhancing bio-availability of 
copper and reducing toxicity [39].  
The Ni(II) ion coordination of properties towards the blocked hexapeptide model                          
-TESHHK- (Ac-ThrGluSerHisHisLys-am) which contains the C-terminal "tail" -ESHH-      
(-Glu-Ser-His-His-Lys-) of histone H2A was studied. At pH above 7.4, Ni(II) complexes 
with the hexapeptide formed a square-planar complex with the peptide fragment SHHK-
(SerHisHisLys-am) [40,41].  





Cu(II) and Ni(II) cations are well known for their ability to interact with histidyl residues in 
peptides, particularly with those containing the N-terminal sequence X–Y–His that is 
encountered in serum albumin [42-44].   The coordinating properties are affected by 
numerous factors, but if an imidazole is present in the side-chain of an amino acid or 
derivatives [45], in small peptides [46,47] or large protein molecules [43], very often this 
group is one of the most effective metal-binding sites of the molecule. 
Investigation of the Cu(II)-cyclic (HGHK) system revealed that cyclic (HGHK) is capable 
of providing a variety of coordination environments for copper(II) ions depending on pH.   
It was shown that cyclic HGHK can form Cu(II) complexes of comparable stability to 
linear, N-terminally protected, AcHGHG [48].   The metal-binding features of 
oligopeptides, including the effect of the number and position of histidine residues within 
the peptide chain have been summarized in a couple of reviews within the last decade 
[49,50].   These have included equilibrium and solution structural investigation of the 
copper(II) and nickel(II) complexes of Gly-Gly-Gly-Histamine (GGGHa) and its  N-
terminally Boc-protected derivative Boc-Gly-Gly-Gly-Histamine (BGGGHa) [51].  
Copper(II) complexes of the His-tripeptide (Cu(II) Xaa–Yaa–His, Xaa–His–Yaa and His–
Xaa–Yaa) molecules are of significant biological importance.   The copper(II) coordination 
of the tripeptides, mostly with Xaa = Yaa = Gly has been extensively investigated, and the 
coordination mode of copper(II) in the oligopeptide complexes with terminally protected 
groups or peptides containing more than one histidine has been established [52].   The 
investigations of the complex formation equilibria of Lys-containing oligopeptides with the 
Cu(II) ion [53,54], supported the view that the ɛ-NH2 of Lys residue interacts with copper, 
but only at alkaline pH; no deprotonation of ɛ-NH2 was found at neutral pH, and under 
physiological conditions protonated Lys residue of metal-peptides can act as an ‘anchor’ for 
biological receptors [55].  
The sarcosine SAR (N-methyl of glycine) was a natural amino acid in muscles and other 
body tissues.   It was metabolized to glycine by the enzyme sarcosine dehydrogenase while 
glycine-N-methyltransferase generates it.   The sarcosine has no known toxicity and was 
identified as a biomarker as invasive prostate cancer.   It was seen to be greatly improved 
during prostate cancer progression to metastasis also could be identified in urine [56].   It 
was found by Mohajane [57] that the Cu-GLY peptides were slightly more stable than the 
Cu-SAR.   The explanation given was the possibility that the methyl group caused a steric 
effect as well as an inductive effect.   However, since the two results were comparable, the 





conclusion was that the N-methylated dipeptides would not affect the stability of the 
complex, but still improve the lipophilicity of the complex, since N-methylated groups are 
more lipophilic than non-N-methylated groups [58].  
1.4 Aims of the Present Research  
The present study concentrates on the design of new drugs that will alleviate the 
inflammation associated with rheumatoid arthritis.   These drugs an required be 
administered dermally and be selective for Cu(II) so that they do not affect the 
speciation of other metal ions in blood plasma.   The ligands are also expected to be 
soluble both in lipids and in water; however, they are believed to be more lipophilic than 
hydrophilic thus promoting dermal absorption of copper.   In general, the ligands are 
expected to have comparable thermodynamic properties to those of glycyl-L-histidyl-L-
lysine [58- 60].   The proposed ligands are expected to form stable and kinetically labile 
complexes with copper. 
 
1.5 Objectives of the Present Research  
 Measurement of formation constants for tripeptides (drugs) with Cu(II), Zn(II) 
and Ni(II) complexes by glass electrode potentiometry data. The 
protonation/deprotonation constants and the equilibrium of the ligand and metal-
ligand complexes will be calculated.   These constants will give information on 
how many dissociable protons each ligand has, how stable the metal-ligand 
complexes are and the distribution of species in solution at different pH. 
 Determination of the structure of the formed complexes in solution using;       
Uv-Vis, ESI-MS and 1H NMR spectroscopy and molecular mechanics (MM) to 
investigate the possible structures.  
 Evaluation of plasma mobilization ability of Cu(II) tripeptide using a computer 
model of blood plasma (ECCLES) to assess the speciation in vivo of the copper 
complexes. 
 Drug administration and distribution studies will be achieved using octanol/water 
and Franz cell at physiological pH of copper complexes at room temperature 
through a Cerasome 9005.   This indicates the possibility of dermal absorption of 
the copper (II).  
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Copper is transported in vivo as the human serum albumin complex.   In vivo, copper exists in 
three different forms: irreversibly bound to metalloproteins like ceruloplasmin, reversibly 
bound to plasma proteins as serum albumin and as low molecular mass (l.m.m) complexes.   
The type of organic ligands in such copper complexes seems to affect and regulate their 
activity.   They (i) neutralize the electric charge of the copper ion, (ii) increase the 
lipophilicity of the complex, facilitating transport through cell membrane, and (iii) intercalate 
to DNA or interact noncovalently with proteins [1].   Human serum albumin (HSA) is the 
most abundant protein found in plasma and shows a typical blood concentration of  
5 g/100 ml.   It is a major metal-binding protein in the body, with about 40µg of copper able 
to bind to the albumin contained in 1 ml of human plasma [2].   The methylated N-terminals 
of amines are more lipophilic than their non-methylated analogues [3,4].   N-methylated 
peptides are also less susceptible to metabolism [5].   Drugs that will be administered 
transdermally are preferred over drugs that will be administered orally; therefore, the ligands 
have to be slightly lipophilic.   However, it has to be achieved without compromising the 
stability of the Cu(II) complexes.   The proposed ligands combine these two ideas and the 
effect of N-methylation of tripeptides on copper(II) complexation and tissue permeability. 
 
2.2 Principles of Drug (Ligand) Design 
Peptides are complex biomolecules and depending on the amino acid composition each 
peptide is unique in its chemical and physical properties.   Although some peptides are easy 
to dissolve in aqueous solutions, a common problem encountered is very low solubility or 
even insolubility of peptides, especially of peptides with hydrophobic amino acids. 
Coordination chemistry of peptides has been studied since the early 1960s [6-8].   An 
important key in metal coordination chemistry is the formation of stable 5- and/or 6-
membered chelate rings through the N-terminal amino, C-terminal carboxylate, and side-
chain donor groups if present [9].   The most important donor atoms of peptide side-chains in 
terms of coordinating metal ions are the imidazole nitrogen of histidine and the amino 
nitrogen of lysine and the amide nitrogen and carbonyl oxygen of peptide linkages can also 
coordinate metal ions, but are less active donor atoms than those in the terminal amino and 
terminal carboxylate groups [6,10].   However, metal ions such as copper promote the 
deprotonation of the amide nitrogen of the peptide bond to form a very stable metal −N− 
bond.   The design of the ligands was based on the structure of human serum albumin (HSA). 




Therefore, the copper(II) ion has the same peptidic binding site at the N-terminus of human 
serum albumin HSA, which is its transfer route in the human body [10-12].  
 
2.3 Solubility of Peptides in Aqueous Solutions 
Peptides shorter than five residues are usually soluble in water or aqueous buffer, except if 
the whole sequence consists of hydrophobic amino acids.   Hydrophilic peptides containing 
>25% charged residues are usually soluble in water or aqueous buffer.   Hydrophobic 
peptides containing 50% and more hydrophobic residues may be insoluble or only partly 
soluble in aqueous solutions.   Peptides containing a very high (>75%) proportion of 
hydrophobic residues are capable of building intermolecular hydrogen bonds (cross-linking), 
thus forming gels in aqueous solutions [13].  
 
2.4 Metal-Binding Properties of Amino Acids and Peptides 
The binding modes of amino acids and tripeptides are polydentate ligands.   Consequently, 
Cu(II) ions can be used to form complexes in order to block functional groups selectively.   
Some of the side-chains in peptides and proteins, especially those of Glu and His, are 
excellent ligands for transition metal ions.   The ability of transition metal ions to complex 
with a variety of groups found in peptides and proteins probably accounts in large measure 
for the toxicity of these cations [14,15].   Peptides are very useful and often specific ligands 
for a variety of metal ions.   They contain a range of potential donor atoms and the complexes 
formed exist in a variety of conformations [16,17].   Among metal ions, Cu(II) and Ni(II) 
have been widely studied and seem to have the most interesting chemistry.   In particular, 
these two metal ions share the peptidic binding site at the N-terminus of human serum 
albumin, which is the transport form of both in the human body [18,19].   In the presence of 
equimolar concentrations of albumin and peptide, and approximately 20-fold excess of        
L-histidine, there is about 18% of Cu(II) present in the forms of Cu(II)-albumin and              
L-histidine-Cu(II)-albumin, 36% in the forms of Cu(II)-peptide and L-histidine-Cu(II)-
peptide, and 46% as Cu(II)-L-histidine.   The extension of the tripeptide chain with an 
additional residue results in an increase of stability of the final 4N complex at the expense of 
the 3N species [16,20-22].   This unusual effect has been interpreted as evidence for the 
presence of a particular conformation of the  C-terminal part of the peptide in the 4N 
complex, stabilised indirectly by Cu(II) [23].   In particular, log KHL (amine protonation) is 
high when Pro or Sar is in the first position of the peptide chain, as a result, of inductive 




effects, and drops towards the value for tetraglycine as the substituent is moved along the 
chain [24,25].    
Previous studies have shown how the pKa values of tripeptides composed of glutamic (Glu), 
glycine (Gly) and histidine (His) residues are influenced by the kind and place of the residue 
in the peptide sequence [26].  
Investigation of the influence of position of residues on the formation constants of copper(II) 
complex with tripeptides and report a systematic study of the effects of types and positions of 
amino acid amino acid residues of tripeptides.   The length of tripeptides between the             
C-terminal and the N-terminal was the same for all these tripeptides in this present study 
because the length of the chain may also affect the solubility of organic compounds       
(Figure 2.1).   The proposed ligands are expected to increase the lipophilicity and may also 
increase the stability of the metal complex by forcing the divalent metal into its favorable 
coordination geometry [27].   The ligands are also expected to promote dermal absorption of 





















































sarcosyl-L-glycyl-L- histidine  
Figure 2.1: Structures of proposed ligands (drug design) used in this study. 
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Glass electrode potentiometry (GEP) has been found to be one of the most reliable and 
accurate methods for measuring equilibrium constants in aqueous solution [1,2].   However, 
the measurement of metal complex stability constants is based on pH metric titrations of a 
ligand with and without metal ions and hence the ligand must be either an acid or a base.   
These coordination equilibria can then be used to approximate the metal ion speciation in 
complex biological systems [3].   In such situations, potentiometric titration, using a glass 
hydronium ion selective electrode, a suitable reference electrode and a sensitive 
potentiometer (a pH meter) may be advantageous. 
 
3.1.1 Principles  
 The primary procedure of using chemicals of a known weight has been applied in 
standardising the acids/bases, which can then be used to standardise other solutions like the 
ligand solutions.   Metal ion solutions should be standardized by described methods [4,5]. 
The titration vessel is filled with analyte solutions of known concentration and volume and 
the standard solutions of the titrant are injected into the titration vessel.   The potential 
difference between the glass electrode and the reference electrode is measured, and these are 
direct measurements since indicators are not used.   The output basically depends on the 
concentrations of the analyte solution and the titrant solution.   The equilibrium constants of 
species have been calculated from the outputs with the potentiometric titrations being carried 
out at a fixed temperature and ionic strength [6,7].  
A Gran plot is constructed to find the end point from the potentiometric data [8,9].   For this 
method, an acceptable plot should have two slopes meeting at one point (end point), and 
should there be any difference between the end points of the two slopes, this indicates CO2 
contamination which could affect the results since CO2 forms carbonic acid in aqueous 
solutions [2-6,10].  
The potentiometric data were here analysed using the computer program equilibrium 
simulation for titration analysis (ESTA) [3].   It was shown that the formation of 
metal/tripeptide complexes is strongly pH dependent as the metal competes with the protons 
bound to ligand.   These data were also used to predict the possible metal/ligand models and 
to predict the distribution of species in solution.  
 
 





The theory of metal complex stability constants and methods used to determine these 
constants has been widely covered in the literature [11,12].   Consider a general metal-ligand 
formation equilibrium involving metal ion (M) and ligand (L); 
M + L  ML 
The concentration equilibrium constant for ML can be expressed as  
 
KML =  
[ML ]
[M][L]
                                                                (3.1) 
And for MLn-1 + L  MLn 
The concentration equilibrium constant can be expressed as; 
KMLn =  
[MLn ]
[MLn−1][L]
                                                        (3.2) 
 
Log K’s for other species MLH-1, MLH-2 do not have a fixed meaning but are defined by the 
equilibrium expression.   For the reaction; 
 ML  MLH-1 + H 
KMLH−1 =  
[MLH−1 ][H]
[ML]
                                                    (3.3) 
 
Log K for the more complicated species ML2H-1, ML2H-2 depends on the pathway of the 
reaction.   There are two (or more) possible routes for the formation of these species.  ML2H-1 
can be formed by; 
ML2  ML2H-1 + H 
KML2H−1 =  
[ML2H−1][H]
[ML2]
                                                 (3.4) 
Or; 
MLH-1 + L  ML2H-1 
KML2H−1 =  
[ML2H−1]
[MLH−1 ][L]
                                                  (3.5) 
 
Similarly, log KML2H-2 from different routes;  
ML2  ML2H-2 + 2H 
MLH-2 + L  ML2H-2 
ML2H-1  ML2H-2 + H 




The stability of these species is therefore better described by the cumulative stability 
constants, log β’s. 
For the reaction;      pM + qL + rH   MpLqHr 
 
Where p, q and r, are stoichiometric coefficients,  
βMpLqHr =
[Mp Lq Hr ]
[M]p[L]q[H]r
                                                        (3.6) 
 
Stepwise equilibrium constants can then be calculated from the β; 
M + L   ML                  𝛽ML  =  KML =
[ML]
[M][L]
                                               (3.7) 
 
ML + L   ML2              𝛽ML2  =  KML KML2 =
[ML2 ]
[M][L]2
                                   (3.8) 
 
ML2 + L   ML3             𝛽ML3  =  KML KML2 KML3 =
[ML3 ]
[M][L]3
                         (3.9) 
 




  (3.10) 
 
The electrode cell is the centre of any potentiometric investigation.   An electrochemical cell 
consists of a test solution surrounding a glass electrode in electrical contact with a reference 
electrode through a salt bridge and can be represented as follows; 
 
 Reference electrode/ salt bridge/ analyte solution/glass electrode 
              Eref                      Ej                                                 Eg  
 
where Eref, the reference electrode potential, has a known constant value and it is not affected 
by the concentration of the analyte solution.   Eg, the potential of the glass electrode varies 
with the concentration of the analyte solution [13,14].   Ej, the liquid junction potential, 
results from a difference in concentrations of the analyte solution and the internal reference 
solution. Ecell, the observed potential is the sum of all three; 
 
                                  Ecell = Eref + Ej + Eg                                                                           (3.11) 




Eg varies with the concentration of the analyte solution and the Nernst equation can be 
written as; 
                               Ecell = Eref + Ej + (Eg0 +
RTln{H}
F
)                                                     (3.12) 
 
where the Eg0  is the standard electrode potential and {H} is the activity of the hydrogen ion.   
The activity of the proton is expressed as; 
                                       {H} =  ϒH[H]                                                                         (3.13) 
 
where  ϒH is the activity coefficient of the hydrogen ion and [H] is the concentration of the 
hydrogen ion.   The ionic strength, I, can be expressed as: 
 
                                   I = 1
2
∑( CiZi)
2                                                                             (3.14) 
 
where Ci is the concentration of the ionic species, i and Zi is the charge of the ion. 
 
If the ionic strength is constant then equation 3.12 can be re-written as: 
 
                                  Ecell = Econstant +
RTln[H]
F
                                                             (3.15) 
                                                       
However, the potential depends on temperature and the relationship between the two varies 
with the activity of the hydrogen ion.   This can be expressed in terms of the slope factor, s. 
                                          
                                          s = 2.30RT
F
                                                                                 (3.16) 
Putting equation 3.16 into 3.15 yields;  
 
                                Ecell = Econstant + s log[H]                                                              (3.17) 
 











All chemicals and reagents were of analytical grade and were used without any further 
purification. Sarcosyl-L-histidyl-L-lysine (SHK), sarcosyl-L-lysyl-L-histidine (SKH), 
sarcosyl-L-histidyl-L-histidine (SHH), sarcosyl-L-lysyl-L-lysine (SKK) and sarcosyl-L-
glycyl-L-histidine (SGH) were purchased from GL Biochem (Shanghai) Ltd and the purity 
was checked by chromatographic methods and potentiometric titrations.   The other 
chemicals were purchased from Sigma and used without further purification.   The metal-ion 
stock solutions were prepared from analytical grade reagents and their concentration was 
checked using EDTA titration.  
 
3.3.2 Preparation of solutions 
The hydrochloric acid (HCl) solution was diluted and the exact concentration was determined 
by titration against standardised NaOH solution prepared from 0.1 mol dm-3 NaOH ampoules 
which were standardized against standard potassium hydrogen phthalate [15].   The ligand 
solution was prepared in standardised HCl (0.02 M) by direct weighing of tripeptides  
(0.01 M).   The metal solutions were prepared by dissolving NiCl2.6H2O, CuCl2.2H2O and 
ZnCl2 (0.01 M) in boiled-out glass-distilled water.   They were standardised by EDTA-
murexide titration using a Metrohm 765 Dosimat automated burette dispensing 0.01 mol dm-3 
EDTA solution. All of the stock solutions were prepared using NaCl as a background 
electrolyte to maintain a constant ionic strength of 0.15 mol dm-3.    All weighing was done to 
5 decimal places on an A&D GH-202 analytical scale balance.    Repeat titrations were done 
to check the reproducibility of the titrations. 
 
 3.3.3 Potentiometric measurements 
All pH-metric measurements were carried out at 25 ͦC and at a constant ionic strength of 0.15 
mol dm-3 (NaCl).   The Metrohm glass electrode was calibrated with a set of Metrohm ion 
analysis pH buffers from which the pH and the Nernstian slopes were determined [9,13].   
The slope varied from 58.71 to 59.19 over the pH range 2.0-11.0, using a Metrohm 
6.0259.100 glass electrode.   The standard electrode potential (E0) and pKw were calculated 
from NaOH/HCl titrations.   E0 ranged between 401.99 and 417.01 millivolts, pKw ranged 
between 13.75 and 13.78.   All the metal titrations were performed using 1:1 metal: ligand 
concentrations. 
 




 3.3.4 Data handling and calculations 
Experimental data were analysed using the computer program, Equilibrium Simulations for 
Titration Analysis (ESTA).   ESTA has a number of tasks. In this study ZBAR, QBAR and 
OBJE tasks were used. 
 
3.3.4.1 Formation and deprotonation functions  
ZBAR task is a simulation unit that uses mass balance equations to characterise the system on 
a point by point basis [3].   This task plots ZH-bar curve for ligand protonation and ZM-bar 
curve for complex formation titrations.   The protonation/deprotonation formation function 
(ZH-bar) is expressed as; 
                                                   ZH−bar =
TH−H+OH
 Tlig
                                                         (3.18) 
where TH is the total concentration of hydronium ions, Tlig is the total concentration of the 
ligand and OH-.   It is possible to estimate pKa values from the half ZH-bar values. 
 
 The complex formation function (ZM-bar) depends on the cumulative protonation 
/deprotonation constants of the ligand to which the metal ion is binding.   This can be 
expressed as; 




                                             (3.19) 
where TM is the total metal concentration, and the free ligand concentration, A, is given by; 
                                                                                        A =
TH−H+OH
∑ (βLHnHn)n
                                                                                    (3.20) 
 
This function assumes or is defined for simple, stepwise complex formation.   If this 
assumption is not true, the curve will deviate and ultimately the free ligand concentration will 
become negative.   Since ZM-bar is plotted against –logA (pA), at this point it is not possible to 
plot the curve as log of a negative number is not defined.   ESTA calculates the residual; 
                                                 Z−barresidual = Zo−bar − Zc−bar                                      (3.21) 
 
where Z0-bar is the observed and ZC-bar is the calculated Z-bar.   A good agreement is 
observed if the observed and calculated Z-bar curves are superimposable.   It is also 
important to know how many protons have been lost upon complexation with a metal ion.   
For this a deprotonation function (QM-bar) is calculated; 




                                                            (3.22) 




where T*H is total concentration or H+ ions in solution at the observed pH.   The mass 
balance equations for T*H and TL can be expressed as; 
TH
∗ = H − OH + ∑ r
NJ
J=1
[Mp Lq Hr ] 
TL = L +  H − OH + ∑ q
NJ
J=1 [Mp Lq Hr ]                             (3.23) 
 
QM-bar can be plotted as a function of pH. ESTA plots QM-bar on the same graph with n-bar 
which is.   The total number of dissociable protons on the ligand in the absence of metal ion. 




r                                                               (3.24) 
 
3.3.4.2 The objective function 
The OBJE task of ESTA optimises titration parameters using a weighted or unweighted least 
squares method.   The objective function, Uobj is given by the following equation; 
 




calc)2                   (3.25) 
 
where N is the total number of experimental titration points; np is the total number of points 
being optimised, ne is the total number of electrodes; Wnq of the qth residual at the nth titration 
point, Yncalc is the calculated variable of the qth residual at the nth titration point and Ynqobs is 
the observed variable of the qth residual at the nth titration point.   Using Gauss-Newton 
methods [16], Equation 3.25 can be expressed as a quadratic; 
 
                                                        Uobj = a +  ptb +
ptHp
2
                                               (3.26) 
 
where a and b are Gauss-Newton quadratic parameter vectors, p is the optimization parameter 
vector and pt is the rearranged form of Equation 3.26 (Hessian method); 
 
                                                          Hsr =
d2Uobj
dpsdpr








3.3.4.3 Standard deviation and Hamilton R-factor 
The standard deviations [17,18] (δ) are errors estimated for the parameters being optimized 
by OBJE and calculated as follows;  
                                                                 δ = (
UobjGrr
N−np
) 1/2                                                (3.28) 
 
OBJE also optimizes the Hamilton R-factor (RH) to check if the model is accurate.   RH is 
expressed as; 
                                                             𝑅𝐻 = (
𝑈𝑜𝑏𝑗
∑ 𝑛𝑒−1 ∑ 𝑊𝑛𝑞(𝑌𝑛𝑞
𝑜𝑏𝑠)2
) 1/2                             (3.29) 
 
RH depends on random errors and the number of variables optimised. Based on estimates of 
the random errors it is possible to calculate a theoretical limiting value for RH and RHlim,  If 
RH is less than RHlim then the model is precise as is statistically possible [19] or the error 
between the observed results and calculated results can be explained by random error.   RHlim 
is expressed as; 
 
                                                             𝑅𝑙𝑖𝑚𝐻 = (
𝑁
∑ 𝑛𝑒−1 ∑ 𝑊𝑛𝑞(𝑌𝑛𝑞
𝑜𝑏𝑠)2
) 1/2                           (3.30) 
Once titration variables have been optimised and converged; the speciation graph can be 
plotted from the initial concentrations.  
 
3.4 Results  
3.41 Protonation titrations 
The protonation constants for sarcosyl-L-histidyl-L-lysine (SHK), sarcosyl-L-lysyl-L-
histidine (SKH), sarcosyl-L-histidyl-L-histidine (SHH), sarcosyl-L-lysyl-L-lysine (SKK) and 
sarcosyl-L-glycyl-L-histidine (SGH) are presented in Tables 3.1-3.5.   The tripeptides contain 
four groups, respectively, which are capable of reversible proton binding.   These groups are 
the carboxyl group of Lys and His, the N3 imidazole nitrogens of His, the N-terminal of Sar 
and the ԑ-amino group of Lys.   In general the standard deviations were small and the RfH was 
less than RlimH thus the model is within the maximum allowed experimental error.   The log K 
values did not differ significantly from the literature values.   The agreement between the 
theoretical and the experimental plot gives us confidence in the results. 
 
 




3.4.1.1 Protonation of sarcosyl-L-histidyl-L-lysine 
The ZH-bar for protonation of sarcosyl-L-histidyl-L-lysine is given in Figure 3.1.   The graph 
levels off between pH 11.4 ant pH 11.7 and then rises until it reaches ZH-bar  = 3 (between 
pH 5.5 and pH 3.6).   The graph rises again from pH 3.5 to pH 2.0.   Protonation constants of 
sarcosyl-L-histidyl-L-lysine were estimated from the half ZH-bar values; log KLH = 10.33, log 
KLH2 = 8.37, log KLH3 = 6.57 and log KLH4= 2.83 and used as starting values in ESTA.  
  
 
Figure 3.1: ZH-bar for the protonation of sarcosyl-L-histidyl-L-lysine. 
 
The final log K’s are given in Table 3.1.   The results obtained are comparable with the 
results obtained for Gly-His-Lys protonation (pKa1=10.44, pKa2=7.93, pKa3=6.53 and     
pKa4=2.91) [20].   The standard deviations are small and the model is accurate since RH is less 
than RHlim.   This gives confidence in the results. 
  
Table 3.1: Stability constants (log βpqr) for sarcosyl-L-histidyl-L-lysine (SHK) βpqr = 
[MpLqHr]/[M]p[L]q[H]r, I = 0.15 mol.dm-3 (NaCl), T = 25 ºC.  S. dev denotes standard 
deviation in logβpqr; RfH is the Hamilton R-factor and RlimH its limit. 










































































The speciation for sarcosyl-L-histidyl-L-lysine protonation titrations is given in Figure 3.2.  
From pH 7.20 to pH 10.85 the most predominate species is mono- protonated.   The plots 
indicate that the ligand solution has a mixture of di-protonated, tri-protonated and tetra- 
protonated species.   The di-protonated species were predominant at pH < 9.59 whereas the 
neutral form of the ligand predominates at pH > 8.9.  
 
 
Figure 3.2: Distribution curve for the protonation of sarcosyl-L-histidyl-L-lysine 
 
 3.4.1.2 Protonation of sarcosyl-L-lysyl-L-histidine 
The ZH-bar function in Figure 3.3 indicates that there are four dissociable protons in the 
sarcosyl-L-lysyl-L-histidine.   From pH 11.05 to pH 11.52, the Sar-Lys-His was completely 
deprotonated (ZH-bar is zero).  
 

































The graph rises from pH 10.87 to pH 6.28.   From pH 6.08 to pH 3.85 the ZH-bar = 3 was 
maintained.   The graph rises from pH 3.63 to pH 2.08 where ZH-bar ≈ 4 was reached.    The 
excellent agreement between the experimental and theoretical curves as well as the low 
standard deviations and Hamilton R-factors lends confidence to this model.   Table 3.2 shows 
calculated log β’s for the sarcosyl-L-lysyl-L-histidine.    
 
Table 3.2: Stability constants (log βpqr) for sarcosyl-L-lysyl-L-histidine (SKH) βpqr = 
[MpLqHr]/[M]p[L]q[H]r, I = 0.15 mol.dm-3 (NaCl), T = 25 ºC.  S. dev denotes standard 
deviation in logβpqr; RfH is the Hamilton R-factor and RlimH its limit. 

























































The calculated speciation graphs in Figure 3.4 show that the solution has a mixture of 
protonated species in the pH range of 2.19-10.85.   This is because of the closeness of the pKa 
values for the protonated sites of the ligand.   At pH =8.80 only the neutral form of the ligand 
species is present in solution. 
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3.4.1.3 Protonation of sarcosyl-L-histidyl-L-histidine  
Figure 3.5 shows the formation function, ZH-bar as a function of pH for the protonation of 
sarcosyl-L-histidyl-L-histidine.   The ZH-bar plot changed direction at pH 6.09-9.26, rose up 
and then levelled off at ZH-bar ≈ 3 at pH 3.44 to 5.19, and increased slightly above pH 2.06.   
This implies that the ligand has four dissociable protons.   The agreement between the 
theoretical and the experimental plot gives us confidence in the results.  
 
 
Figure 3.5: ZH-bar for the protonation of sarcosyl-L-histidyl-L-histidine. 
 
The experimental protonation constants of sarcosyl-L-histidyl-L-histidine are presented in 
Table 3.3.   The standard deviations were small and the RH was less than RHlim thus the model 
was within the maximum allowed experimental error.   
     
Table 3.3: Stability constants (log βpqr) for sarcosyl-L-histidyl-L-histidine (SHH) βpqr = 
[MpLqHr]/[M]p[L]q[H]r, I = 0.15 mol.dm-3 (NaCl), T = 25 ºC.  S. dev denotes standard 
deviation in logβpqr; RfH is the Hamilton R-factor and RlimH its limit. 









































































The speciation diagrams in aqueous solution of sarcosyl-L-histidyl-L-histidine (Figure 3.6), 
confirms that the SHH-H3 and SHH-H4 species are predominant in the pH range 2.07 – 7.09 
and the species SHH-H and SHH-H2 dominates in the pH range 4.01 – 10.05, respectively.  
 
 
     Figure 3.6: Distribution curve for the protonation of sarcosyl-L-histidyl-L-histidine. 
 
3.4.1.4 Protonation of sarcosyl-L-lysyl-L-lysine  
Figure 3.7 indicates that sarcosyl-L-lysyl-L-lysine contains four measurable protonation sites 
as revealed by the levelling off of the ZH-bar = 4 at the pH 2.02, indicating that four protons 
were added to the ligand. 
 
 


































The function levels to zero at a high pH of 11.49, indicating that this completely deprotonated 
at this pH.   The protonation of sarcosyl-L-lysyl-L-lysine has been reported in Table 3.4.   
However, the errors for log β’s are small and RfH is less than RHlim.   An excellent agreement 
between theoretical and experimental functions supports and gives confidence in the results.  
 
 Table 3.4: Stability constants (log βpqr) for sarcosyl-L-lysyl-L-lysine (SKK) βpqr = 
[MpLqHr]/[M]p[L]q[H]r, I = 0.15 mol.dm-3 (NaCl), T = 25 ºC.  S. dev denotes standard 
deviation in logβpqr; RfH is the Hamilton R-factor and RlimH its limit. 
























































 These four species are also confirmed by the distribution species diagram in Figure 3.8.   The 
mono-protonated and the di-protonated species are predominant in the pH range 6.63 -10.58 
respectively in aqueous solution. 
 
 
Figure 3.8: Distribution curve for the protonation of sarcosyl-L-lysyl-L-lysine. 
 
3.4.1.5 Protonation of sarcosyl-L-glycyl-L-histidine 
Figure 3.9 shows average number of protons bound to sarcosyl-L-glycyl-L-histidine as a 
function of pH. The protonation function curve indicates that there are three dissociable 
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terminal amino groups and the rising of the curve at pH =2.05 is indicative of a proton adding 
to the imidazole nitrogen group.   At high pH (pH = 9.74) the curve levels off at zero 
indicating that the last proton is lost at this pH.   
 
 
Figure 3.9: ZH-bar for the protonation of sarcosyl-L-glycyl-L-histidine. 
 
The superimposability of the theoretical and experimental ZH-bar curves of Sar-Gly-His 
concentrations and this, as well as the low standard deviations and Hamilton R-factors 
confirm the validity of this model.   Log β’s values are given in Table 3.5. 
 
Table 3.5: Stability constants (log βpqr) for sarcosyl-L-glycyl-L-histidine (SGH) βpqr = 
[MpLqHr]/[M]p[L]q[H]r, I = 0.15 mol.dm-3 (NaCl), T = 25 ºC.  S. dev denotes standard 
deviation in logβpqr; RfH is the Hamilton R-factor and RlimH its limit. 









































The calculated and species distribution curves shown in Figure 3.10 indicate that the solution 
has a mixture of mono-protonated; di-protonated and tri-protonated species in the pH range 



















Figure 3.10: Distribution curve for the protonation of sarcosyl-L-glycyl-L-histidine. 
 
3.4.2 Complex formation titrations 
Two functions, the formation (ZM-bar) and the deprotonation functions (Q-bar) were used to 
investigate the reproducibility of the experimental data and the reliability of evaluated log βpqr 
values.   The complex formation function, ZM-bar, measures the average number of ligands 
bound per metal ion due to complexation.   This function is plotted against the negative 
logarithm of the free ligand concentration (logA).   The deprotonation function, Q-bar, 
indicates the average number of protons released due to complexation and is plotted against 
the pH of the solution.   Q-bar is evaluated in conjunction with the n-bar function, which 
measures the average number of protons that would be bound to the ligand in the absence of 
complexation.   These two functions serve two purposes.   Firstly, they give a visual check on 
the experimental data and secondly, their shape gives an idea of the speciation model 
applicable to the system. However, if the curves at different metal: ligand ratios are not 
superimposable, protonated or polynuclear species formation is indicated, while if the ZM-bar 
curves fan back hydroxyl species formation is indicated.  
 
3.4.2.1 Sarcosyl-L-histidyl-L-lysine complexes  
3.4.2.1.1 Cu(II)/Sarcosyl-L-histidyl-L-lysine 
Figure 3.11 shows the complex formation function (ZM-bar) levels off at value of ≈1.0 for 
mononuclear species formation indicating the presence of CuSHK as a major species.   It is 
independent of component ratios and concentrations, suggesting a complex stoichiometry of 
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Figure 3.11: ZM-bar as a function of pA for Cu(II) sarcosyl-L-histidyl-L-lysine complex. 
 
of mixed-hydroxo complex species [21].   The stability constants (log βpqr) are given in Table 
3.6.   The standard deviations are small and RfH is less than RlimH.   This lends confidence to 
the model. 
 
Table 3.6: Stability constants (log βpqr) for Cu(II) sarcosyl-L-histidyl-L-lysine complex  βpqr 
= [MpLqHr]/[M]p[L]q[H]r, I = 0.15 mol.dm-3 (NaCl), T = 25 ºC. S. dev denotes standard 
deviation in logβpqr; RfH is the Hamilton R-factor and RlimH its limit, nT is the number of 









The total number of dissociable protons on the ligand (n-bar) and the total number protons 
lost upon complexation of Cu(II) with SHK (QM-bar) are shown in Figure 3.12.   At a pH of 
2.50, QM-bar is greater than zero indicating that complexation has already commenced.   The 







































































indicating the release of approximately three protons due to complex formation.    Form pH 
5.50 to pH 8.84 QM-bar is parallel to n-bar indicating that no more protons are displaced by 
the metal in this pH range.   Above pH 8.7 the curve rises again moving above the n-bar 
curve, which indicates that hydroxo species have begun to form.   The theoretical plot and the 
practical plot are superimposable; this gives confidence in the results. 
 
 
Figure 3.12: QM-bar as a function of pH for Cu(II) sarcosyl-L-histidyl-L-lysine complex. 
 
 
Figure 3.13: The distribution curve for the Cu(II) sarcosyl-L-histidyl-L-lysine complex. 
 
The species distribution curves in above Figure 3.13 shows that different species predominate 
at different regions of the pH range.   At pH 7.05 a high % Cu(II) peak is observed for 
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The ZM-bar and Q-bar plots concur with the species distribution curves as shows in Figure 
3.13. 
 
3.4.2.1.2 Ni(II)/Sarcosyl-L-histidyl-L-lysine  
ZM-bar for Ni(II) sarcosyl-L-histidyl-L-lysine is given in Figure 3.14. At pA 11.02 the graph 
rises and fans back at pA 6.09 indicating the formation of hydroxo species.   The optimised 
stability constants are given in Table 3.7.    
 
 
Figure 3.14: ZM-bar as a function of pA for Ni(II) sarcosyl-L-histidyl-L-lysine complex. 
 
Table 3.7: Stability constants (log βpqr) for Ni(II) sarcosyl-L-histidyl-L-lysine complex  βpqr = 
[MpLqHr]/[M]p[L]q[H]r, I = 0.15 mol.dm-3 (NaCl), T = 25 ºC. S. dev denotes standard 
deviation in logβpqr; RfH is the Hamilton R-factor and RlimH its limit, nT is the number of 








The QM-bar for Ni(II) sarcosyl-L-histidyl-L-lysine titrations is given in Figure 3.15.   Sar-
His-Lys has four dissociable protons and it loses three protons upon complexation with 







































































and NiSHK-H-2.   The distribution graph for Ni(II) Sar-His-Lys titrations is shown in Figure 
3.16, where the complexation occurs from pH 5.26 to pH 10.86. 
 
 
Figure 3.15: QM-bar as a function of pH for Ni(II) sarcosyl-L-histidyl-L-lysine complex. 
 
 
Figure 3.16: The distribution curve for the Ni(II) sarcosyl-L-histidyl-L-lysine complex.  
 
3.4.2.1.3 Zn(II)/Sarcosyl-L-histidyl-L-lysine  
ZM-bar for Zn(II) Sar-His-Lys is given in Figure 3.17.   The curves resemble those of Zn(II) 
Sar-His-Lys in the splitting pattern when varying the metal to ligand ratio.   The fanning back 
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Figure 3.17: ZM-bar as a function of pA for Zn(II) sarcosyl-L-histidyl-L-lysine complex. 
 
Figure 3.5 shows that the Q-bar function increases in the pH range of 5.29 to 7.37 followed 
by rising up from pH 9.0, indicating hydroxo species formation.   This also means that 
complexation begins at about pH 5.20.  
 
 
Figure 3.18: QM-bar as a function of pH for Zn(II) sarcosyl-L-histidyl-L-lysine  complex. 
 
Table 3.8 shows four species obtained in the complexation of Zn(II) with Sar-His-Lys and 
their stability constants.   The standard deviations are reasonably low, and the Hamiltonian R-
































Table 3.8: Stability constants (log βpqr) for Zn(II) sarcosyl-L-histidyl-L-lysine complex  βpqr 
= [MpLqHr]/[M]p[L]q[H]r, I = 0.15 mol.dm-3 (NaCl), T = 25 ºC. S. dev denotes standard 
deviation in logβpqr; RfH is the Hamilton R-factor and RlimH its limit, nT is the number of 









Speciation for Zn(II) Sar-His-Lys is given in Figure 3.19.   The ZnSHK-H distribution curve 
is for small species and reaches to 36.78 % formation at pH 6.97. From pH 6.18 to 10.73, the 
predominant species present in solution is ZnSHK and from the pH 7.89 to 10.85 the hydroxo 
species (ZnSHK-H-1 and ZnSHK-H-2) have begun to form. 
 
 
Figure 3.19: The distribution curve for the Zn(II) sarcosyl-L-histidyl-L-lysine complex.  
 
3.4.2.2 Sarcosyl-L-lysyl-L-histidine complexes 
3.4.2.2.1 Cu(II)/Sarcosyl-L-lysyl-L-histidine  
Figure 3.20 shows the formation of function curve, ZM-bar against pL for Cu(II) sarcosyl-L-
lysyl-L-histidine at 25ºC in 0.15 M NaCl.   The complexation curves for various metals to 
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the formation of hydroxo or mixed-hydroxo complex species in solution.   The agreement 
between the theoretical and practical complex formation curves at different metal to ligand 
ratios supports the potentiometric model chosen in data analysis.  
 
 
Figure 3.20: ZM-bar as a function of pA for Cu(II) sarcosyl-L-lysyl-L-histidine complex. 
 
 
Figure 3.21 shows that at pH values 2.52 the deprotonation function Q-bar of zero indicates 
that no protons have been displaced due to complexation.   The splitting pattern of the curves 
follows that of the formation curves the protonation function n-bar has a value of 3.53 at this 
pH confirming that the ligand is still protonated at low pH.   For pH values above 4.50 the 
deprotonation function Q-bar rapidly rises to intersect the protonation curve, n-bar, at a pH of 
5.80, reaching a maximum value of about 3.32. The falling of the curves at about pH 6.40 
shows that complexation is complete.   At about pH 10.09 levelling off at Q-bar = 2 is due to 
the formation of hydroxo species CuSKH-H-2.   This means that two additional protons have 


















Figure 3.21: QM-bar as a function of pH for Cu(II) sarcosyl-L-lysyl-L-histidine complex. 
 
Table 3.9 shows that four species were obtained in the complexation of Cu(II) with Sar-Lys-
His (SKH) and their stability constants are also shown.   The reported standard deviations of 
the log βpqr values obtained from potentiometry are reasonably low.  
 
Table 3.9: Stability constants (log βpqr) for Cu(II) sarcosyl-L-lysyl-L-histidine complex  βpqr 
= [MpLqHr]/[M]p[L]q[H]r, I = 0.15 mol.dm-3 (NaCl), T = 25 ºC. S. dev denotes standard 
deviation in logβpqr; RfH is the Hamilton R-factor and RlimH its limit, nT is the number of 









The species distribution curve for the complexes of Sar-Lys-His and Cu(II) is shown in 
Figure 3.22.   At pH 4.0, there is 100 % of the free metal ion species.   Around pH 4.24, the 
CuSKH-H species began to form and this is a very small species.   The proportion of this 
species began to fall at pH 5.15, where the formation of CuSKH-H-1 commenced; it was 
formed at the expense of the CuSKH species.   The maximum amount of CuSKH-H-2 species 










































































Figure 3.22: The distribution curve for the Cu(II) sarcosyl-L-lysyl-L-histidine complex. 
 
3.4.2.2.2 Ni(II)/Sarcosyl-L-lysyl-L-histidine  
The ZM-bar for the complexes of sarcosyl-L-lysyl-L-histidine and Ni(II) is shown in Figure 
3.23.   It starts to fan back indicating that the NiSKH species did not predominant in solution 
due to the formation of hydroxo complex species.  
 
 
Figure 3.23: ZM-bar as a function of pA for Ni(II) sarcosyl-L-lysyl-L-histidine complex. 
 
Sar-Lys-His (SKH) has four dissociable protons and it loses two protons upon complexation 

































constants of the complexes of Ni(II) and Sar-Lys-His are presented in Table 3.10.   These 
stability constants were not similar to those of the species from the Cu(II) system.  
 
 
Figure 3.24: QM-bar as a function of pH for Ni(II) sarcosyl-L-lysyl-L-histidine complex. 
 
Table 3.10: Stability constants (log βpqr) for Ni(II) sarcosyl-L-lysyl-L-histidine complex  βpqr 
= [MpLqHr]/[M]p[L]q[H]r, I = 0.15 mol.dm-3 (NaCl), T = 25 ºC. S. dev denotes standard 
deviation in logβpqr; RfH is the Hamilton R-factor and RlimH its limit, nT is the number of 








The distribution graph for Ni(II) Sar-Lys-His is given in Figure 3.25.   There was no chemical 
change from pH 2.00 to pH 5.70.   At pH 6.18, the NiSKH species began to form.   A 
maximum of 30.42 % of this species was observed in solution at pH 6.86. The NiSKH-H-1 
species began to form around the same pH.   A maximum of 96.87 % of NiSKH-H-1 species 
was observed at pH 8.57.   NiSKH-H-2 species began to form at pH 8.57 and there were only 





























































Figure 3.25: The distribution curve for the Ni(II) sarcosyl-L-lysyl-L-histidine complex. 
 
3.4.2.2.3 Zn(II)/Sarcosyl-L-lysyl-L-histidine  
ZM-bar for Zn(II) sarcosyl-L-lysyl-L-histidine is given in Figure 3.26.   The curves do not 
level off and resemble those in the splitting pattern obtained by varying the metal to ligand 
ratio.   The rising and fanning back of the complex formation function at pA of 7.01 is 
indicative of mixed hydroxo species. 
 
 

































Table 3.11 shows the formation of four species in the complexation of Zn(Il) with Sar-Lys-
His and their stability constants.   The standard deviations are reasonably low and are not far 
from those obtained in the Cu(II)- Sar-Lys-His complexation.  The Hamiltonian R-factor is 
low thus giving confidence for the model chosen. 
 
Table 3.11: Stability constants (log βpqr) for Zn(II) sarcosyl-L-lysyl-L-histidine complex  βpqr 
= [MpLqHr]/[M]p[L]q[H]r, I = 0.15 mol.dm-3 (NaCl), T = 25 ºC. S. dev denotes standard 
deviation in logβpqr; RfH is the Hamilton R-factor and RlimH its limit, nT is the number of 









However, Sar-Lys-His loses two protons upon complexation with Zn(II).   QM-bar rises from 
pH 6.56 and levels off between pH 8.41 and pH 10.96 (Figure 3.27).   There is a small 
depression between pH 10.10 and pH 10.90.   This shows that ZnL forms between pH 6.52 
and pH 10.28.   The depression is due to the formation of hydroxo species. 
 
 










































































Furthermore, the calculated species distribution curves (Figure 3.28) show that the protonated 
species (ZnSKH-H) is present at pH 7.32 and a very small amount of Zn(II) also exists.   
There were ZnSKH, ZnSKH-H-1 and ZnSKH-H-2 in the whole pH range investigated 
indicating complexed Zn(II) ions in the solution. 
 
 
Figure 3.28: The distribution curve for the Zn(II) sarcosyl-L-lysyl-L-histidine complex.  
 
3.4.2.3 Sarcosyl-L-histidyl-L-histidine Complexes 
3.4.2.3.1 Cu(II)/Sarcosyl-L-histidyl-L-histidine 
ZM-bar for Cu(II) and sarcosyl-L-histidyl-L-histidine titrations is given in Figure 3.29.   At 
pA of 14.00 the ZM-bar rising and fanning back of the complex formation function was 
indicative of mixed hydroxo species. 
 

































The species and their equilibrium constants are given in Table 3.12.   The errors are small; 
RfH is less than RlimH and the agreement between the theoretical and experimental formation 
and deprotonation functions as well as the reproducibility of repeat titrations at different 
metal: ligand ratio also lends confidence to the model. 
 
Table 3.12: Stability constants (log βpqr) for Cu(II) sarcosyl-L-histidyl-L-histidine complex  
βpqr = [MpLqHr]/[M]p[L]q[H]r, I = 0.15 mol.dm-3 (NaCl), T = 25 ºC. S. dev denotes standard 
deviation in logβpqr; RfH is the Hamilton R-factor and RlimH its limit, nT is the number of 









QM-bar for Sar-His-His titration is given in Figure 3.30.   Sar-His-His loses three protons 
upon complexation with Cu(II).   QM-bar rises at pH 2.76, drops at pH 6.14 and levels off 
between pH 9.13 and pH 10.96 indicating the formation of hydroxo species.  
 
 











































































The speciation graph for this titration is given in Figure 3.31.   Complexation began at pH 
3.10.   There are four species formed between Cu(II) and Sar-His-His, CuSHH-H and 
CuSHH start forming around the same pH. 
 
 
Figure 3.31: The distribution curve for the Cu(II) sarcosyl-L-histidyl-L-histidine complex. 
 
3.4.2.3.2 Ni(II)/Sarcosyl-L-histidyl-L-histidine 
ZM-bar for Ni(II) sarcosyl-L-histidyl-L-histidine titrations is given in Figure 3.32. The ZM-bar 
curves start to fan back almost immediately indicating that the NiSHH species did not 
predominate in solution. 
 
 
































QM-bar is shown in Figure 3.33. Sar-His-His has four dissociable protons and it loses three 
protons upon complexation with Ni(II).  
 
Figure 3.33: QM-bar as a function of pH for Ni(II) sarcosyl-L-histidyl-L-histidine complex. 
 
Stability constants for species formed between Ni(II) and Sar-His-His are given in Table 
3.13.   Four species have been formed in solution.   The theoretical and experimental of 
formation and deprotonation functions are in excellent agreement and reproducibility of 
repeat titrations at different metal to ligand ratios.   
 
Table 3.13: Stability constants (log βpqr) for Ni(II) sarcosyl-L-histidyl-L-histidine complex  
βpqr = [MpLqHr]/[M]p[L]q[H]r, I = 0.15 mol.dm-3 (NaCl), T = 25 ºC. S. dev denotes standard 
deviation in logβpqr; RfH is the Hamilton R-factor and RlimH its limit, nT is the number of 









The distribution for Ni(II)/ Sar-His-His titrations is given in Figure 3.34.   NiSHH-H and 
NiSHH start forming around the same pH.   The pH range 5.61–10.05 indicates the presence 










































































Figure 3.34: The distribution curve for the Ni(II) sarcosyl-L-histidyl-L-histidine complex. 
 
3.4.2.3.3 Zn(II)/Sarcosyl-L-histidyl-L-histidine  
ZM-bar was observed for the Zn(II) sarcosyl-L-histidyl-L-histidine titrations as shown in 
Figure 3.35.   As the titration continues, at pA 6.74 the curves rise steeply and fan back 
indicating the formation of mixed-hydroxo complex species. 
 
 
Figure 3.35: ZM-bar as a function of pA for Zn(II) sarcosyl-L-histidyl-L-histidine complex. 
 
The deprotonation function (Q-bar) in Figure 3.36 shows that at the beginning of the titration, 

































Sar-His-His has four dissociable protons and it losses two protons upon complexation with 
Zn(II). 
 
Figure 3.36: QM-bar as a function of pH for Zn(II) sarcosyl-L-histidyl-L-histidine complex. 
 
The calculated formation constants in Table 3.14 have reasonably low standard deviations 
and are comparable to those of copper(II) complexation.   The Hamilton RH-factors indicate 
that the model is a good description of the equilibria occurring in solution. 
 
Table 3.14: Stability constants (log βpqr) for Zn(II) sarcosyl-L-histidyl-L-histidine complex  
βpqr = [MpLqHr]/[M]p[L]q[H]r, I = 0.15 mol.dm-3 (NaCl), T = 25 ºC. S. dev denotes standard 
deviation in logβpqr; RfH is the Hamilton R-factor and RlimH its limit, nT is the number of 








The distribution for Zn(II) Sar-His-His titrations is given in Figure 3.37.   Four species 










































































Figure 3.37: The distribution curve for the Zn(II) sarcosyl-L-histidyl-L-histidine complex.  
 
3.4.2.4 Sarcosyl-L-lysyl-L-lysine Complexes 
3.4.2.4.1 Cu(II)/Sarcosyl-L-lysyl-L-lysine 
Figure 3.38 shows the complex formation curves as a function of pA for the sarcosyl-L-lysyl-
L-lysine with Cu(II).   The ZM-bar levels off at ≈ 1.0 indicating that CuSKK is the 
predominant species in solution.   Moreover, the fanning back for higher metal to ligand 
ratios indicates loss of an amide proton upon metal coordination. 
 
 
Figure 3.38: ZM-bar as a function of pA for Cu(II) sarcosyl-L-lysyl-L-lysine complex. 
 
The deprotonation function in Figure 3.39 rises to maximum value of about 2.57 at pH 7.21 
































complexation.   In the pH range 9.06-11.00 these curves level off due to the presence of 
hydroxo and/or mixed hydroxo species or rather formation of the CuSKK-H-2 species.  
 
 
Figure 3.39: QM-bar as a function of pH for Cu(II) sarcosyl-L-lysyl-L-lysine complex. 
 
Equilibrium constants for Cu(II) Sar-Lys-Lys titrations are given in Table 3.15.   The CuSKK 
species is more stable than NiSKK and ZnSKK species of this ligand.   The good agreement 
between theoretical and experimental formation and deprotonation functions as well as low 
standard deviations and Hamilton R-factors confirm the validity of this model. 
 
Table 3.15: Stability constants (log βpqr) for Cu(II) sarcosyl-L-lysyl-L-lysine complex  βpqr = 
[MpLqHr]/[M]p[L]q[H]r, I = 0.15 mol.dm-3 (NaCl), T = 25 ºC. S. dev denotes standard 
deviation in logβpqr; RfH is the Hamilton R-factor and RlimH its limit, nT is the number of 








The speciation graphs in Figure 3.40 show species formed by the complexation of Sar-Lys-









































































CuSKK-H-1 species reaching 49% formation.   It is also observed that complexation 
commences at about pH 4.13 when the protonated CuSKK-H species was formed. 
 
 
Figure 3.40: The distribution curve for the Cu(II) sarcosyl-L-lysyl-L-lysine complex. 
 
3.4.2.4.2 Ni(II)/Sarcosyl-L-lysyl-L-lysine 
The formation function for the Ni(II) Sar-Lys-Lys titrations in Figure 3.41 rises  at pA 8.17. 
The fan back of ZM-bar is indicative of hydroxo and/or mixed hydroxo species in solution. 
 
 

































QM-bar for Ni(II) Sar-Lys-Lys titrations is given in Figure 3.42.   QM-bar begins at pH 5.26 
and levels off due to the presence of hydroxo species between pH 8.46 and pH 10.86.                    
Sar-Lys-Lys lost two protons upon complexation with Ni(II). 
 
 
Figure 3.42: QM-bar as a function of pH for Ni(II) sarcosyl-L-lysyl-L-lysine complex. 
 
Three species were observed for this titration and the equilibrium constants are given in Table 
3.16.   The theoretical and experimental formation and deprotonation functions were in good 
agreement; also there was reproducibility of repeat titrations at various metal: ligand ratios.   
 
Table 3.16: Stability constants (log βpqr) for Ni(II) sarcosyl-L-lysyl-L-lysine complex  βpqr = 
[MpLqHr]/[M]p[L]q[H]r, I = 0.15 mol.dm-3 (NaCl), T = 25 ºC. S. dev denotes standard 
deviation in logβpqr; RfH is the Hamilton R-factor and RlimH its limit, nT is the number of 







The calculated species distribution graph given in Figure 3.43 indicates the presence of 
NiSKK species as the predominant species reaching 83.68 % formation in the pH range 7.09-
10.85 for the Sar-Lys-Lys titrations.   From pH 8.57 to pH 10.85, Ni(II) exists as NiSKK-H-1. 




























































Figure 3.43: The distribution curve for the Ni(II) sarcosyl-L-lysyl-L-lysine complex. 
 
3.4.2.4.3 Zn(II)/Sarcosyl-L-lysyl-L-lysine 
The metal ion appears to coordinate to sarcosyl-L-lysyl-L-lysine.   This is revealed by the 
ZM-bar in Figure 3.44 which rises and fans back at pA 6.79.   This is indicative of the 
formation of mixed hydroxo species.  
 
 




































The calculated formation constants for this model presented in Table 3.17 have very low 
standard deviations and Hamilton RH-factors.   This lends confidence to the model. 
 
Table 3.17: Stability constants (log βpqr) for Zn(II) sarcosyl-L-lysyl-L-lysine complex  βpqr = 
[MpLqHr]/[M]p[L]q[H]r, I = 0.15 mol.dm-3 (NaCl), T = 25 ºC. S. dev denotes standard 
deviation in logβpqr; RfH is the Hamilton R-factor and RlimH its limit, nT is the number of 








The QM-bar rises at pH 5.34 and levels off at QM-bar = 1.88 at pH 9.18 as shown in Figure 
3.45.   It drops before it rises again. This indicates that Sar-Lys-Lys loses two protons upon 
complexation with Zn(II). 
 
 
Figure 3.45: QM-bar as a function of pH for Zn(II) sarcosyl-L-lysyl-L-lysine complex. 
 
The distribution graph (Figure 3.46) shows that there was free Zn(II) in solution at pH 2.50 to 
pH 8.80.   ZnSKK-H species exist between pH 6.18 and pH 9.59, ZnSKK occurs between pH 











































































Figure 3.46: The distribution curve for the Zn(II) sarcosyl-L-lysyl-L-lysine complex. 
 
3.4.2.5 Sarcosyl-L-glycyl-L-histidine Complexes 
3.4.2.5.1 Cu(II)/Sarcosyl-L-glycyl-L-histidine 
Figure 3.47 shows the ZM-bar curve for Cu(II) sarcosyl-L-glycyl-L-histidine titrations.      
The deviation of ZM-bar function from its normal shape indicates that the other, more 
complex species are forming.   ZM-bar function curves fan back indicating the formation of 
deprotonated or hydroxide species.   The agreement between the theoretical and experimental 
valves gives confidence in the model. 
 
 

































The deprotonation function for the complexes of Cu(II) with Sar-Gly-His is plotted in Figure 
3.48.   Sar-Gly-His has three dissociable protons and complexation by Cu(II) causes it to lose 
two protons. At pH 5.81, the QM-bar rises to about Q-bar = 2.83.   This could happen when 
one of the amides loses a proton or a coordinated water molecule loses a proton. 
Thermodynamically these two processes are the same. From pH 5.81 to pH 9.33, the n-bar 
and Q-bar curves run parallel in this pH range no change in complexation was taking place.  
  
 
Figure 3.48: QM-bar as a function of pH for Cu (II) sarcosyl-L-glycyl-L-histidine complex. 
 
Cu(II) and Sar-Gly-His form three species in solution (CuSGH-H, CuSGH-H-1 and               
CuSGH-H-2).   Equilibrium constants for these species are shown in Table 3.18.   The 
standard deviations were small therefore the model was within the maximum allowed 
experimental error. 
 
Table 3.18: Stability constants (log βpqr) for Cu(II) sarcosyl-L-glycyl-L-histidine complex 
βpqr = [MpLqHr]/[M]p[L]q[H]r, I = 0.15 mol.dm-3 (NaCl), T = 25 ºC. S. dev denotes standard 
deviation in logβpqr; RfH is the Hamilton R-factor and RlimH its limit, nT is the number of 

































































The species distribution curve for the complexes of Sar-Gly-His and Cu(II) is shown in 
Figure 3.49.   The CuSGH-H species is formed from pH 3.21 to pH 5.61, and a maximum of 
61.48% CuSGH-H-1 is formed.   About 100% of the CuSGH-H-2 was reached at pH 7.66 









The protonation constants of all five tripeptides are presented in Table 3.19.  The tripeptides 
contain four groups, respectively, which are capable of reversible proton binding.   These 
groups are the carboxyl group of Lys and His, the N3 imidazole nitrogens of His, N-terminal 
of Sar and the ԑ-amino group of Lys.  
 
Table 3.19: Protonation constants of all tripeptides in this study.  
 






























































Cu(II) MLH MLH-1 MLH-2




The N-terminal amino group of Sar is less basic than the ԑ-amino group of Lys due to the 
former’s proximity to the electron-withdrawing carbonyl group of the first peptidic bond.   
The corresponding pKa value is 2.21 log units lower than that of free Sar (10.01).  The 
experimental values of the protonation constants of tripeptides estimated using ESTA1were 
optimised using ESTA2.   These titrations have not been reported before; however, the effect 
of the N-terminal amino group of sarcosine on the log values is not the same in glycine 
peptides due to the inductive effect possessed by the methyl substituent.   In particular, pKa of 
N-terminal amine protonation is high when sarcosine is in the first position of the peptide 
chain as a result of inductive effects. 
 
The equilibrium constants of the reaction progress of Cu(II) tripeptide species are given in 
Table 3.20.   The measurable interaction between the Sar-His-Lys and Cu(II) starts at pH 3.1 
and, as is shown by the concentration distribution curves calculated at 1:1 ratio, CuLH is the 
first species appearing in measurable concentration formed by deprotonation of the one 
amide, N-terminal amino and nitrogen N3-imidazole (it is still protonated below pH 6) and 
water molecule (pKa = 4.52).   The value of pKa of [Cu(Him)]2+ =4.07, which is consistent 
with the presence of a Cu(II) ion coordinated  by amino, dissociated amide and N3-imidazole 
nitrogens [22].   The stoichiometry of the CuLH complex suggests that the His and the Lys 
residues remain protonated. 
 
Table 3.20: Equilibrium constants of the reaction progress of Cu(II) tripeptide species. 
  

































At pH 6.75 CuL is the predominant species in the range 4-10.   Further deprotonation of this 
complex take place with pKa’s of 9.44.   On the other hand, the presence of the ԑ-amino 
function of the Lys residue in Sar–His–Lys does not affect complexation equilibria.   Similar 
prominence of the CuLH-1 complex was also found for Cu(II) complexes of Ala–His [23], 
Gly–His–Gly [24,25], glycylhistamine [26], and Gly–His–Lys [25,27,28].   The crystal 
structures of Cu(II) complexes with Gly-His [29], Gly–His–Gly [30] and Gly–His–Lys [31] 
support the 3N coordination in the CuLH-1 complex.   The formation of the CuLH-2 species 




by the deprotonation of lysine side-chain amino group, and the pKa = 10.65 which is almost 
the same as of free tripeptide (SHK). 
In the pH range 2.5-11 and with the ratio of Cu(II): Sar-Lys-His at 1:1 it was shown that the 
coordination of Cu(II) starts in acidic solution at a pH of about 4 and the first species formed 
is CuLH.   The stability constant of CuLH (17.20) is higher than that of complexes of the 
same formula, and only 1N coordination of Cu(II) with the peptides GGH (12.24) [32], 
GGHist (12.02) [23], DAH (12.85) [24] and of 2N coordination [NH2, Nim] (CuLH) with 
HVH (15.41) [33], suggesting the participation of two nitrogen atoms in the coordination 
sphere of Cu(II).   The CuLH species might contain two nitrogen atoms [NH2, N−] 
coordinated in the equatorial plane of the Cu(II).   The stoichiometry of the CuLH species 
suggests that the His and the Lys residues remain protonated and uncoordinated.   In more 
basic solutions, complexes of CuL stoichiometry are formed.   The CuLH released a proton 
with pKa 4.70, which is comparable to the values for peptides with peptide nitrogen 
coordination [34,35-37].   The proton is abstracted from the next amide nitrogen, forming a 
complex with stoichiometry CuL.   The formation of the CuL complex suggests the 
participation of four nitrogen atoms [NH2, 2N−, Nim] in the equatorial plane of the Cu(II) 
forming a very stable chelate ring.   This is typical of analogous Cu(II) complexes with 
peptides containing the N-terminal sequence Xaa-Yaa-His [33,38,39].   The stoichiometry of 
the CuL species and the pH range of its formation, which is below the deprotonation range of 
the His side chain in free tripeptide, indicates that the imidazole ring of His and ԑ-amino 
group of Lys residues remain protonated [40].   The next species formed upon pH increase is 
CuLH−1.   This species predominates in the pH range 4.0-10.7.   This phenomenon is 
characteristic of the stability caused by the tetradentate chelate ring [NH2, 2N−, Nim] of 
Cu(II) complexes with peptides containing the N-terminal sequence Xaa-Yaa-His [41,42].  
 
Above pH 9.0 deprotonation of the CuLH−1 species takes place with a pKa value of 10.35, 
forming the CuLH−2 species.    In the case of CuLH−2, although the ԑ-amino group of the Lys 
residue is deprotonated it remains uncoordinated.   This is similar to the analogous Cu(II) 
complexes with tetrapeptide SHHK- and SAHK-, and other peptides containing the Lys 
residue [35,39].   The pKa value of 10.35 is very similar to the pKa corresponding to the 
protonation of the ԑ-amino group of the Lys. 
 
For Sar-His-His, in the pH range 2.0-6.3, the refinement of potentiometric data indicates that 
only mononuclear species are present in solution even in the presence of excess of Cu(II). 




The first species in solution, CuLH, is formed by the N3-imidazole (1), N-terminal amino, 
carbonyl oxygen and one water molecule.   The imidazole group of His in third position will 
be protonated [22].   Loss of a proton from the MLH species gives rise to the ML complex. 
The pKa for this process CuLH CuL +H+ is 4.39 was formed by stepwise deprotonation 
of the second imidazole ring.   This is suggesting that the presence of the Cu(II) ion in the 
complex has no impact on the proton from the 2nd His supports binding of the N-terminal 
amino group, imidazole nitrogens, carbonyl oxygen and water molecule  to the metal ion.  
 
Two species are present above pH~6.5 in the Cu(II) sarcosyl-L-histidyl-L-histidine 
complexes.   The CuLH-1 species (pKa = 6.74), this can be compared to the same process 
occurring with glycinamide (pKa = 6.8), where it is known that coordination swap from the 
amide oxygen to amide nitrogen.   The conversion of CuLH−1 to CuLH−2 occurs in the 
reaction CuLH-1 CuLH-2+H+ (pKa = 9.05).   At this pKa value the deprotonation of  
Sar-His-His with Cu(II) can be interpreted either by the deprotonation of the water molecule 
or by the deprotonation and coordination of a second amide group to Cu(II).   For the binding 
of Cu(II) with the amide nitrogens of the peptide systems, the deprotonation of the second 
amide nitrogen seems to be easier for His-His peptides; the pKa of the reaction is 9.00, which 
is around 1.5 units lower than that for His-Xaa-His peptides.   The pKa value of 9.05 is in the 
range expected for metal assisted deprotonation of the amide proton [43-45], rather than 
hydrolysis of the complex.   On the other hand, the coordination chemistry of any peptides 
with the amino acid sequence X–Y–His has already been described by the exclusive 
formation of the species CuLH-2 with [NH2, 2×Namide, Nim] coordination [38,46].   The same 
finding was obtained in the Cu(II) with Sar-Lys-His and Sar-Gly-His complexes.   With  
Sar-His-His axial N3 coordination of His at position II cannot be excluded. 
 
The coordination of Cu(II) with Sar-Lys-Lys starts below pH 5, with MLH species formation. 
The concentration of this species reaches its maximum at pH 6, binding all the Cu(II) ion and 
remaining the only species in solution up to pH 8. At higher pH values, the CuLH species 
undergoes three deprotonation steps leading to the species CuL, CuLH-1 and CuLH-2.   The 
pKa value of CuLH CuL+H+ is compatible with amide deprotonation and the type of 
coordination (-NH, N-, 2H2O).   The next two deprotonation steps CuL CuLH-1+H+ and 
CuLH-1 CuLH-2+H+, are very close to the protonation pKa values of the two side Lys, 
suggesting that no interaction occurs between the ԑ-NH2 groups and the copper ion.   The 




above hypothesis is true, because the geometry of the CuLH species is not the same of the 
others species (see Chapter 4).  
The concentration of the MLH species for Cu(II) Sar-Gly-His reaches its maximum at pH 5, 
binding all the Cu(II) ion and remaining the only species in solution.   The CuLH species 
undergoes two deprotonation steps leading to the species CuLH-1 and CuLH-2.   The CuLH is 
always present in very low concentration.   Its binding mode can be interpreted either by the 
coordination of the N-terminal amino and neighbouring carbonyl oxygen donors with the 
protonated imidazole side chain or by the monodentate coordination of an imidazole nitrogen 
with a protonated amino group.   Earlier studies led to the conclusions that N3 of imidazole is 
the primary binding site of these peptides [38,47,48], but careful consideration of the result 
obtained for the species formed at higher pH strongly supports the existence of amine binding 
for all possible stoichiometries.   Its presence can be verified in all cases and its signal 
overlaps well with those of tripeptide with [NH2, CO, Nim] coordination.   The second species 
in solution CuLH-1 is formed by binding of the N-terminal amino group, imidazole nitrogens 
and two peptide groups.   However the imidazole group of the histidine is still protonated.   
As a consequence, the latter coordination mode can be suggested as the cause of the high 
stability, CuLH-2, appears to have the same coordination as CuLH-1, but the imidazole group 
of the histidine was deprotonated [49].  
 
3.6 Conclusions 
Investigation of the Cu(II), Ni(II) and Zn(II) complexes of sarcosyl-L-histidyl-L-lysine 
(SHK), sarcosyl-L-lysyl-L-histidine (SKH), sarcosyl-L-histidyl-L-histidine (SHH), sarcosyl-
L-lysyl-L-lysine (SKK) and sarcosyl-L-glycyl-L-histidine (SGH) showed a significantly 
different coordination behavior of all tripeptides in acidic/neutral and basic pH range.   The 
results presented in this study approved that the metal ion complexation strongly depends on 
the position of histidine in the amino acid sequence of the tripeptide molecules.   The detailed 
potentiometric analysis of Cu(II) ions with all tripeptides, around pH~7, could be best fitted 
by the involvement of a species CuL or CuLH-1  into the model, these species being proposed 
to coordinate equatorially with the N-terminal amino group, deprotonated amide, the 
imidazole nitrogens with N3 and a water molecule.  
The CuLH and CuL species of Sar-His-Lys (SHK) was more stable than those of CuLH with 
the others tripeptides.   The CuLH-1 complexes of Sar-Lys-His (SKH) were more stable than 
those of Cu(II) with the others tripeptides.   This CuL species was not observed in the Sar-




Gly-His (SGH) system.   The similar stability of CuLH-2 species formed for Sar-Lys-His 
(SKH) and Sar-Gly-His (SGH) system, which were more stable than others tripeptides.   
 
The Cu(II) Gly tripeptides, such as Gly-Gly-His, saturate the copper coordination plane at the 
most acidic pH of 4.4, compared to other peptide ligands.   Consequently, the best ligand for 
binding copper depends on the particular application [50].   However, the methyl group does 
have an inductive effect making the Sar tripeptides more basic than Gly tripeptides.   A 
similar effect is seen with the Cu(II) Sar-His-Lys and Sar-Gly-His complexes, the 
thermodynamic stabilities of these N-terminal amino group of sarcosine are more basic than 
the analogous tripeptides in slightly basic solution.   For the Cu(II) tripeptides with the 
sarcosine-containing ligand the presence of coordination is supported by spectroscopic 
methods (see Chapter 4).   
 
Moreover, all tripeptides in the present study are more stable and selective for Cu(II) than 
Ni(II) and Zn(II).   This trend agrees with the Irving-Williams stability series [51,52]. 
However, the ZnL of the Sar-Lys-Lys species was 1.01 log units more stable than the NiL 
complex (Table 3.16 and Table 3.17), which runs contrary to the  Irving-Williams stability 
series [53].  
 
Finally, the results presented here confirm that Cu(II) forms stable complexes with all the 
tripeptides studied.   This is the first requirement of the main aim of this study, which is to 
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CHAPTER FOUR  





















4.1 UV-VISIBLE SPECTROSCOPY  
4.1.1 Introduction  
Transition metal ions exhibit absorption bands in the visible region of the spectrum as the 
species are highly coloured [1].   These colours come from electronic transitions between 
energy levels whose spacings correspond to the wavelengths available in visible light.   In 
complexes, these transitions are frequently referred to as d-d transitions because they involve 
molecular orbitals that are mainly metal d in character.   Since this spacing depends on 
factors such as geometry of the complex, the nature of the ligands present, and the oxidation 
state of the central metal atom, electronic spectra of complexes can provide valuable 
information related to bonding and structure [2,3].   Absorption spectroscopy is an excellent 
technique for following ligand-binding reactions, enzyme catalysis and conformational 
transitions in proteins and nucleic acids [4].   It has been used to predict the structures of 
Cu(II) complexes [5-7].   The spectrophotometry provides an additional method for 
comparing possible chemical models which are not available with potentiometry.  
Because the Uv-Visible spectra of most complexes contain broad overlapping absorption 
bands, parameter correlation arises and therefore, it is not usually possible to evaluate 
stability constants as precisely from spectrophotometric data as compared to potentiometric 
data. The potentiometric data may lead to a more precise analysis of the wrong model, 
whereas spectrophotometric data will indicate the correct model but give a less precise 
analysis of it.   Therefore, it is necessary to combine both spectrophotometric and 
potentiometric data for defining the chemical model and for evaluation of the stability 
constants respectively [8,9].   As a result, UV-visible spectrophotometry is used as a 




The absorption of electronic transitions is observed in bands where the energy of each band 
corresponds to the difference in energy between the initial and final states.   The relative 
intensities of absorption bands are governed by a series of selection rules.   According to the 
spin selection rule the transitions between states of different spin multiplicity are forbidden, 




ie., transitions between 4A2 and 4T1 states are "spin-allowed," but between 4A2 and 2A2 are 
"spin-forbidden".   
The Laporte selection rule, states that the only transitions with a change of parity, gerade to 
ungerade (g → u) and ungerade to gerade (u → g) but not (g → g) or (u → u) are allowed. 
This would mean that all d-d transitions in octahedral complexes are Laporte forbidden and 
therefore many complexes will be colourless.  
However, most ions do not have perfect symmetry, and are distorted so that the centre of 
symmetry is destroyed, resulting in mixing (hybridization) of d and p orbitals [2,3,8]. Even 
complexes that do have perfect symmetry can give rise to d-d transitions, as this symmetry is 
momentarily distroyed by molecular vibration.    Since electronic transitions are much faster 
than molecular vibration, it is the instantaneous symmetry of the complex that is important 
(cf Franck Condon principle) [10].   This breaks down the Laporte selection rule resulting in 
partially allowed transitions. The greater the distortion, the greater the intensity of the 
transition.  
Many inorganic complexes, including copper complexes, absorb in the visible region 
 (400-700 nm). The chemistry of the copper(II) ion differs from that of the copper(I) ion in 
that while the latter has a closed shell configuration (Ar)d10 and forms diamagnetic and 
colourless complexes, the former has an incomplete d shell configuration (Ar)d9 and its 
complexes are predominantly paramagnetic and highly coloured [11].   The aqueous 
chemistry of copper is largely devoted to Cu(II) compounds because Cu(I) compounds are 
quite unstable in aqueous solution. Cu(II) peptide complexes have been studied as models for 
Cu(II)-protein interactions. It was observed that strong Cu(II)-N(peptide) bonds are formed 
when protons are ionized from peptide nitrogen atoms. In the present study biological 
important donor atoms such as N(amino), N(imidazole), O(carboxylate), O(peptide), H2O and 
OH- were studied [12].  
The Beer-Lambert-Bouger law, commonly called Beer's law, is the fundamental law 
governing the attenuation of radiation by a specific absorbing species in spectrometry. 
                                                              A = ƐbC                                                                 (4.1) 
where A is the absorbance, Ɛ is the molar extinction coefficient, b is the path length of the 
sample cell and C is the molar concentration of the absorbing species. If the analyte solution 




is a mixture of different species, the total absorbance at a specific wavelength (Aλ) can be 
expressed as; 
                                  Aλ = b(Ɛ1λC1 + Ɛ2λC2 + Ɛ3λC3 + ⋯ ƐnλCn)                               (4.2) 
 
where the superscript λ is a parameter at a certain wavelength and subscripts 1, 2, 3…n are 
absorbing species. Equation 4.2 can be simplified; 
                                                               Aλ = b ∑ ƐiλCi                                                       (4.3) 
 
Billo has proposed the most popular methods of structure determination using valves of  
λmax [12]. Calculated λmax is expressed as; 
                                                               λmax =  
103
niνi
                                                            (4.4) 
where ni is the number of equatorial donor groups and νi is the ligand field of the complex.  
Ligands used in this study have four main electron donor atoms; N-donor of the amide,  
N-donor of the imidazole, N-donor of the amine, O-donor of the carboxylate and O-donor of 
water.   According to Billo [12], subsequently Sigel and Martin [13] and E. Prenesti et al.[14] 
the contribution of the different groups to λmax are given in Table 4.0. 


















(νi 10-3 cm-1) 




Aqueous solutions of 1:1 metal: tripeptides ratios were prepared in the pH range 2.0-11.0. 
The concentration of the tripeptide and metal were 0.005 M.   The visible spectra of the 
Cu(II) and Ni(II) complexes were recorded on a Hewlett Packard 8452A Diode Array 
Spectrophotometer in the range 200-820 nm.   The solutions were kept at a constant 
temperature of 25 °C.   The spectra at different pH values need to be deconvoluted to yield 
spectra for individual species.   This was done using UV_SPECTRA.EXE, an in-house 
computer program, which requires the concentration of each and every species in each 
solution and then calculates the molar extinction coefficients of the species at different 




wavelengths.   The stability constants determined from potentiometry are used to calculate 
each species concentration at the different valves of pH.   Since each wavelength is treated 
independently, if the data can be deconvoluted and smooth curves are obtained it lends 
confidence to the potentiometric data [15,16].  
4.1.4 Results and Discussion 
4.1.4.1 Copper Tripeptide Complexes 
4.1.4.1.1 Cu(II)/Sarcosyl-L-histidyl-L-lysine 
Uv-Vis results for Cu(II) Sar-His-Lys are given in Figure 4.1.   The spectrum of [Cu(H2O)6]2+ 
agrees well with literature.   The values of  λmax= 610 nm and Ɛmax =67.94 dm3 mo1-1cm-1 for 
CuLH are in agreement with data from Gergely and co-workers [17] as well as, Morris and  
Martin [18] for copper(II) complex of glycyl-L-histidine.   The value of λmax calculated for 
the Uv-Vis band, by the equation proposed by Billo [12], if the coordinating groups are 
amino, N3-imidazole nitrogens and carbonyl oxygen  in addition to a water molecule is 656 
nm.   This is 46 nm more than the observed maximum wavelength.   A difference of 46 nm 
between the calculated and the experimental value of λmax may be due the fact that 
coordination to the carboxylate oxygen is axial.   Billo’s method [12] assumes no axial 
coordination.   At pH 6.75 CuL is the predominating species and the Cu-O amide bond breaks 
and the Cu-N amide bonds forms.   The calculated d–d spectrum for CuL shows a band with 
λmax at 607 nm (Ɛmax = 61.39 dm3 mo1-1cm-1).  
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Table 4.1 shows observed calculated λmax, when the Billo equation is used and the 
coordination of an amino-N, deprotonated amide-N, imidazole-N and a water molecule is 
assumed [12].   The formation of CuLH−1 and CuLH−2 is followed by a significant blue shift 
of the d–d absorption maximum, with a decrease of λmax value compared to the preceding 
species.   Such a change is in line with the deprotonation of a coordinated water molecule to 
form a hydroxo species. Proposed structures are given in Figure 4.2. 
 
Table 4.1: Uv-Vis spectra Ɛmax (dm3.mol-1.cm-1) and λmax (nm) experimental and calculated 
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-NH, N- , Nim, H2O 
 
-NH, N- , Nim, OH- 
 























































Figure 4.2: Proposed structures of complexes formed between Cu(II) and Sar-His-Lys. 
 
The formation of the CuLH-2 species does not have an impact on the spectrum which implies 
that there is no change in the metal coordination environment.   Formation of MLH-2 is then 
assigned to the deprotonation of the lysine side-chain amino group.   The pH at which this 
occurs is 10.65, which is similar to the pKa of the free tripeptide (SHK). 
 
4.1.4.1.2 Cu(II)/Sarcosyl-L-lysyl-L-histidine  
Results for Cu(II) Sar-Lys-His are given in Figure 4.3.   The CuLH species could not be 
detected spectroscopically because to its overlap with CuL in the speciation diagram and its 
very low concentration.  
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Experimental and calculated λmax for the complex species are given in Table 4.2.   The 
spectroscopic parameters of CuL, CuLH-1 and CuLH-2 species suggest the participation of 
four nitrogen atoms [NH2, 2N−, Nim] in the equatorial plane of Cu(II) ions forming a very 
stable chelate ring, typical for analogous Cu(II) complexes with peptides containing the 
 N-terminal sequence Xaa-Yaa-His [19-21]. However, the raw data for Sar-Lys-His was 
different in that there was no shifting of the single absorption band during the titration.   The 
λmax at 525 nm, is similar to the values for 4N Cu(II) complexes with; λmax = 525 nm,  
HVH [20]; λmax = 520 nm, DAH [22]; λmax = 520 nm, SSH [22]; λmax =520 nm, DAHK [23].   
The CuLH−1 species predominates in the pH range 4.0-10.7.   This phenomenon is 
characteristic of the stability caused by the tetradentate chelate ring [NH2, 2N−, Nim] of 
Cu(II) complexes with peptides containing the N-terminal sequence Xaa-Yaa-His [19,20,21]. 
 
Table 4.2: Uv-Vis spectra Ɛmax (dm3.mol-1.cm-1) and λmax (nm) experimental and calculated 
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-NH, 2 N- , Nim 
 
The ԑ-amino group of the Lys is deprotonated, but remains uncoordinated.   This is similar to 
the analogous Cu(II) complexes with tetrapeptide SHHK- and SAHK-, and other peptides 





































Figure 4.4: Proposed structures of complexes formed between Cu(II) and Sar-Lys-His. 
 
4.1.4.1.3 Cu(II)/Sarcosyl-L-histidyl-L-histidine 
Results for Cu(II) Sar-His-His are given in Figure 4.5. λmax= 630 nm for CuLH indicates that 
Cu(II) coordinates to amino, N3-imidazole nitrogens, carbonyl oxygen and in addition to a 
water molecule [20,26]. The λmax of CuL is very similar (610 nm), which indicates that the 
coordination sphere is the same. The difference between the two species is that the 
uncoordinated imidazole is protonated in CuLH.    A small blue shift is observed for CuL 
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Experimental and calculated values of λmax for the complex species are given in Table 4.3. 
The band shifts to a much lower maximum wavelength when CuLH-1 forms.   This can be 
explained by a bond rearrangements; Cu-Oamide bond breaks and Cu(II) coordinates to the 
Namide.   This suggest that Cu(II) coordinates to amino-N, deprotonated amide-N, imidazole-N 
and a water molecule.   There is another band shifts to a lower maximum wavelength of 525 
nm, when CuLH-2 forms, this is suggest an increase of electron density around the metal ion. 
The results of the Uv-Vis spectra absorption spectroscopy are consistent with the findings of 
species distribution that CuLH-2 is the major species detected above pH 10.63 and the 
determined λmax was close to those determined for Cu(II)-oligopeptide complexes with a 
suggested [-NH, 2N-, Nim] type environment [29,30].   The proposed structures are given in 
Figure 4.6. 
 
Table 4.3: Uv-Vis spectra Ɛmax (dm3.mol-1.cm-1) and λmax (nm) experimental and calculated 
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Figure 4.6: Proposed structures of complexes formed between Cu(II) and Sar-His-His. 
 
4.1.4.1.4 Cu(II)/Sarcosyl-L-lysyl-L-lysine 
The CuLH species geometry is not the same as that of the anther species (CuL, CuLH-1 and 
CuLH-2).   This conclusion is fully supported by spectroscopic results, reported in Figure 4.7 
and summarised in Table 4.4.   The absorption spectra of CuLH as characterised by Uv-Vis 
spectroscopy, show that the wavelength of maximum absorption is 660 nm, close to the 
calculated value of 654 nm, which can be computed by means of the empirical formula 
developed by Sigel and Martin [13] for the coordination of two nitrogen atoms to Cu(II)  
[-NH, N-, 2H2O]. 
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Table 4.4: Uv-Vis spectra Ɛmax (dm3.mol-1.cm-1) and λmax (nm) experimental and calculated 





































-NH, N- , 2 H2O 
 
-NH, 2 N- ,  COO- 
 
-NH, 2 N-, COO- 
 
-NH, 2 N-, COO- 
 
Predicted structures are given in Figure 4.8. In the CuL, CuLH-1 and CuLH-2 species the 
tripeptide binds the copper ion in a tetradentate complex by its N-terminal amino group via 
N, the first two amide nitrogens and the C-terminal carboxylate group via O.   This way of 
coordination is typical of tripeptides, like Gly-Gly-Gly (GGG) in CuLH-2 [13].   The values 
of λmax= 540 nm and Ɛmax = 216.10 dm3 mo1-1cm-1 for CuLH-2 are in very good agreement 







































H2N CuLH-2  
Figure 4.8: Proposed structures of complexes formed between Cu(II) and Sar-Lys-Lys. 







Figure 4.9: Uv-Vis spectra of different species for the Cu(II) Sar-Gly-His system.  
 
Figure 4.9 shows that the Uv-Vis spectroscopic data, obtained for the Cu(II) Sar-Gly-His 
species formed at high pH, strongly support the existence of amine binding for all possible 
stoichiometries.   Unfortunately, the low concentration of the CuLH species does not make it 
possible to calculate the spectroscopic data of this species.   Table 4.5 shows the absorption 
spectra of CuLH-1 and CuLH-2 as characterised by Uv-Vis spectroscopy. 
 
Table 4.5: Uv-Vis spectra Ɛmax (dm3.mol-1.cm-1) and λmax (nm) experimental and calculated 
values are given together with possible donor groups for Cu(II) with sarcosyl-L-glycyl-L-
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The proposed structures are given in Figure 4.10. The λmax is 530 nm, close to the value of 
533 nm, which can be computed by means of the empirical formula developed by Sigel and 
Martin [32] for the coordination of an N-terminal amino group, the two amide nitrogens and 
the imidazole group via N3.   This way of coordination is typical of tripeptides, like Gly-Gly-
His (GGH) in CuLH-2 [33]. The values of λmax= 530 nm and Ɛmax =172.45 dm3mo1-1cm-1 for 
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Figure 4.10: Proposed structures of complexes formed between Cu(II) and Sar-Gly-His. 
 
4.1.4.2 Nickel Tripeptide Complexes 
4.1.4.2.1 Ni(II)/Sarcosyl-L-histidyl-L-lysine 
The absorption spectra and electronic spectra for individual species of the Ni(II) Sar-His-Lys 
complexes, as a function of pH, are given in Figure 4.11.   At pH 5 the solution colour starts 
to change from light green to yellow.   The deprotonation of two or more amide nitrogens in 
nickel(II) peptide complexes is often followed by fundamental changes of Uv-Vis spectra, 
representing a geometrical shift of the complexes from octahedral (light green) to square 
planar (yellow) structures [25,34,35].  
 
 
























Table 4.6 shows the wavelength and molar extinction coefficient values corresponding to 
maximum absorption of the Ni(II) species formed in solution with possible donor groups for 
this ligand. On the other hand, the individually calculated λmax band of NiLH-1                  
(λmax = 435 nm, Ɛ = 67.56 M-1 cm-1) supports unambiguously amino, peptide, imidazole 
nitrogens and hydroxide donors in the coordination sphere [36].  
 
Table 4.6: Uv-Vis spectra Ɛmax (dm3.mol-1.cm-1) and λmax (nm) experimental value, with possible 
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4.1.4.2.2 Ni(II)/Sarcosyl-L-lysyl-L-histidine  
The results for Ni(II) Sar-Lys-His are given in Figure 4.12.   The first species formed is 
probably NiL at pH value around 6.32.   In contrast, the NiL, NiLH−1 and NiLH−2 species 
present similar spectroscopic parameters, supporting the idea of the same coordination in all 
modes of Ni(II) ions.  
 
Figure 4.12: Uv-Vis spectra of different species for the Ni(II) Sar-Lys-His system.  
 
The maximum wavelength near 420-430 nm, for these complex species are comparable with 
the values for analogous 4N [NH2, 2N−, Nim] Ni(II) complexes with the Gly-Gly-Histamine 


















Ni(II) NiL NiLH-1 NiLH-2




simultaneous equatorial coordination of the imidazole ring of His, the N-terminal amino 
group and the two amide nitrogens, in a square-planar Ni(II) arrangement, is suggested.   A 
very stable tetradentate ring is thus formed, typical for analogous Ni(II) complexes with 
peptides containing the N-terminal sequence Xaa-Yaa-His [38,39]. Experimental valves of 
λmax are given in Table 4.7. 
 
Table 4.7: Uv-Vis spectra Ɛmax (dm3.mol-1.cm-1) and λmax (nm) experimental value, with possible 
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4.1.4.2.3 Ni(II)/Sarcosyl-L-histidyl-L-histidine 
Figure 4.13 shows the Uv-Vis spectroscopic data obtained at pH 4. The first species, which 
appears in high concentration, is NiLH2.   For representative concentration distribution curves 
see Figure 3.34 (Chapter 3).  
 
 
Figure 4.13: Uv-Vis spectra of different species for the Ni(II) Sar-His-His system.  
 
If the logarithmic protonation constants of both the imidazole groups from logβNiLH2 are 
subtracted (18.09–5.90–7.17), the value obtained suggests predominant N-terminal amino 
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peptide).   In this species, both imidazole groups are still protonated.   Upon increasing the 
pH, cooperative release of one proton occurs and the NiL species appears in measurable 
concentration.   The analysis of the data suggests that the bonding mode of  NiL formed with 
Sar-His-His is the same as it is in NiL of Gly-His, but the imidazole group of the second 
histidine is still protonated [40].  
Table 4.8 shows experimental valves of λmax and the composition of the species NiLH-1 of 
similar coordination mode which is the most likely.   Above pH 6.29 the previously 
colourless sample turns yellow. This change in the colour, which can be attributed to a single 
absorption band (λmax = 430 nm), strongly suggests the formation of square-planar 
complexes. This behaviour is similar to that of the Ni(II)-Gly-His species, which is formed 
below pH 8. The most stable coordination mode of occurs via the terminal amino-N, peptide-
N and imidazole-N donors [41]. As a consequence, the latter coordination mode found in the 
high stability planar complex of NiLH-2, for which the individually calculated spectrum has a 
λmax at 430 nm and Ɛ = 127.31 M-1 cm-1, suggests the coordination of a deprotonated peptide-
N [18] at the fourth equatorial site.  
Table 4.8: Uv-Vis spectra Ɛmax (dm3.mol-1.cm-1) and λmax (nm) experimental value, with possible 
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Above pH 7.5 the previously colourless sample turns yellow.   The absorption spectra 
confirmed that above pH 7.5 planar species NiL, NiLH-1 and NiLH-2 are present with a 
characteristic λmax at 425 nm. When the pH increases the NiL species appears in measurable 
concentration.   The analysis of the data suggests that the bonding mode of NiL formed with 
Sar-Lys-Lys is the same as it is in NiLH-2 of Gly-Gly-Gly, but the ԑ-amino group of both 
lysine residues are still protonated [42].   The spectrum show in Figure 4.14 also confirms 
amide deprotonation and coordination of the amide nitrogen donor atoms, resulting in the 




same species as reported for Cu(II). In the formation of NiLH-1 and NiLH-2 species, the two 
protons lost are assigned to deprotonation and de-coordinated of two lysine side-chain 
ԑ-amino groups. The pKa valves of 10 and 10.47 respectively, were almost the same as these 
for free Sar-Lys-Lys.   
 
 
Figure 4.14: Uv-Vis spectra of different species for the Ni(II) Sar-Lys-Lys system.  
 
The experimental valves of λmax with possible donor groups and molar extinction coefficients 
are given in Table 4.9.   The valve of λmax = 425 nm, from literature supports unambiguously 
the presence of amino, two deprotonated amide nitrogens and a carboxylate group in the 
coordination sphere [36].  
 
Table 4.9: Uv-Vis spectra Ɛmax (dm3.mol-1.cm-1) and λmax (nm) experimental value, with 
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4.2 1H NMR SPECTROSCOPY 
4.2.1 Introduction 
Proton magnetic resonance spectroscopy (1H NMR) is an analytical chemistry technique used 
to determine the structure of molecules.   It can also be used to assign the site of protonation 
or the structure of metal complexes.   In the case of Cu(II), the protons near the site of 
coordination generally show characteristic broad signals or shifts in the 1H NMR spectrum of 
the coordinated species verses its uncoordinated counterparts [43,44].   The structural features 
of Cu(II) complexes can be studied by 1H NMR despite the broadening of the signal caused 
by the presence of the metal unpaired electron, provided that exchange conditions are 
sufficiently fast to observe an average between the free and the bound ligand [45].   The 
broadening can be a “through bond effect” (Fermi contact interaction) or a “through space 
effect” which is dependent on the distance between the paramagnetic center and the observed 
nucleus.   The differential effect of the metal ion on the ligand can then be used to determine 
the structure of the complex. 
 
4.2.2 Experimental 
1H-NMR experiments were performed on a Bruker Avance 400MHz spectrometer.   The one- 
dimensional experiments were carried out in 1: 9 D2O: H2O mixtures at 25 °C. The pH of the 
solutions was adjusted with NaOH/HCl.   A CRISONmicro pH meter equipped with a 
Metrohm glass electrode was used to measure the pH. The spectra were recorded in the pH 
range 2.00-11.00 with tert-butyl alcohol as an internal reference.   NMR spectra were 
recorded using the zgesgp pulse sequence.   This sequence effectively suppresses the solvent 
signal using excitation sculpting.    The common pre-saturation technique could not be used 
as this also suppresses amide protons through chemical exchange. Spectra were recorded at 
different pH values and at different copper concentrations [43,46,47].   The data were 
processed using MestReNova version 9.1 software.  
 
4.2.3 Results 
4.2.3.1 Protonation Titrations 
In 1H NMR spectroscopy, the diamagnetic contribution to chemical shift dominates over the 
paramagnetic contribution.   This makes non-exchanging, carbon-bound protons a good probe 




of local electron density and thus group-specific ionization.   The range of influence of  
a protonating moiety can be studied using a homologous series of monoprotic systems [48].  
4.2.3.1.1 Protonation of the sarcosyl-L-histidyl-L-lysine 
Figure 4.16 shows the 1H NMR spectra obtained at different pH values.   The assignments of 
the spectra are indicated and follow the numbering in Figure 4.15.   In going from low to high 
pH, the signals a and b were the first to shift from low to high field.   This is ascribed to 
deprotonation of the imidazole nitrogen group.   These signals started shifting at low pH and 














Figure 4.15: The structure of the Sar-Lys-His shows the proton labels in Figure 4.16 & 4.17. 
 
 
Signal d shifts between pH 5.5 and 9.0.   This indicates that the terminal amine is being 
deprotonated in this pH range. From pH 8.5 to pH 11.5 the lysine Hԑ proton shifts as the 
lysine side-chain is deprotonated. The change in chemical shifts as a function of pH of 
protons near e possible coordination sites is shown in Figure 4.17.   Based on these results, 
the sequence of protonation of sarcosyl-L-histidyl-L-lysine is; the pKa= 8.5. of 2.283 
corresponded to the protonation of the carboxylic group, the protonation of the imidazole 
nitrogens was at pKa = 6.57, the terminal -NH corresponded to pKa = 8.37 and the N-terminal 
























Figure 4.16:1H NMR spectra of Sar-Lys-His form pH 2.02 to pH 11.01. Note the break in the 
f1 dimension at 4.4 ppm. The proton assignments are according to Figure 4.15. 
 
 
Figure 4.17: Change of chemical shifts of selected protons of Sar-Lys-His as a function of 
pH. The assignment is given in Figure 4.15. 
 
 
4.2.3.1.2 Protonation of the sarcosyl-L-histidyl-L-histidine 
Figure 4.19 shows the 1H NMR spectra obtained at different pH values.   The assignment of 
the protons is given in Figure 4.18.   From the potentiometric results, Sar-His-His has 4 
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amine proton.   The signals a1, a2 and b1, b2 were the first to shift from low to high field.   
These assignments were complicated by the presence of two His residues in the tripeptide 
sequence. What is clear is that the two a protons and the two b protons have a differential 
shift.   That is they shift apart and then back together again indicating that first imidazole a2 












Figure 4.19: 1H NMR spectra of Sar-His-His form pH 2.02 to pH 11.01. Note the break in 





























Signal e started to shift from pH 7.37.   This is due to the deprotonation of the terminal amine 
nitrogen.   Figure 4.20 shows a plot of selected protons of SHH as a function of pH.  
Finally, the pKa value of the carboxyl group of His (pKa = 2.3) could not be observed, 
potentiometrically, since it occurred at a very low pH.  
 
 
Figure 4.20: Change of chemical shifts of selected protons of Sar-His-His as a function of 
pH. The assignment is given in Figure 4.18. 
 
 
4.2.3.1.3 Protonation of sarcosyl-L-lysyl-L-lysine 
The proton labels for Sar-Lys-Lys are given in Figures 4.21 and the 1H NMR spectra in 
Figure 4.22.   The changes of chemical shifts of selected protons are given in Figure 4.23.   
Signal a shifted from pH 8.13 to pH 10.91.   Since the spectra are recorded in D2O/H2O the 
amide protons are observed at ~ 8.2 ppm.   Between pH 2.0 and 3.0 the one amide doublet 
shift significantly as the terminal lysine carboxylic acid is deprotonated.   Above pH 5-6 these 

















































Figure 4.22: 1H NMR spectra of Sar-Lys-Lys form pH 2.02 to pH 11.01. Note the break in 
the f1 dimension at 4.4 ppm. The proton assignments are according to Figure 4.21. 
 
 
Figure 4.23: Change of chemical shifts of selected protons of Sar-Lys-Lys as a function of 
pH. The assignment is given in Figure 4.21. 
 
The signals that shift the most are signals c and d assigned to the protons of the α-carbon of 
the N-terminal and the protons of the methyl substituent respectively.   These signals shift 
mostly from pH 6.13 to pH 10.91, Log KLH3 = 7.80, which indicates the protonation of the 
amine terminal.   Signal b2 shifted between pH 2.02 and pH 4.22. Log KLH4 = 3.11. These 
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4.2.3.1.4 Protonation of Sarcosyl-L-glycyl-L-histidine 










Figure 4.24: The structure of the Sar-Gly-His shows the proton labels in Figures 4.25 &4.26. 
 
Figure 4.25 shows the 1H NMR spectra.   Change of chemical shifts of protons near the 
possible coordination sites of the free Sar-Gly-His as a function of pH is shown in Figure 
4.26.  Going from low to high pH, the signals a and b were the first to shift to high field.   
This is due to the protonation of the imidazole nitrogen group.   These signals showed a shift 
from pH 2.30 to pH 9. Signal e2 shifted from pH 8.32 to pH 10.37.   This is due to the 
protonation of the N-terminal amino group of the Sar-residue.   The amide protons are 
observed at ~ 8.2 ppm in D2O/H2O.   In the pH range 2.3- 5.8 the one amide doublet shifts 
significantly as the C-terminal histidine carboxylic acid is deprotonated (pKa = 2.3).  
 
 
Figure 4.25: 1H NMR spectra of Sar-Gly-His form pH 2.02 to pH 11.01. Note the break in 





















Figure 4.26: Change of chemical shifts of selected protons of Sar-Gly-His as a function of 
pH. The assignment is given in Figure 4.24. 
 
 
4.2.3.2 Complex formation titrations 
The chemical shifts of protons near the possible coordination sites of the Cu(II) complexes 
are shown as a function of pH in Figures 4.27 to 4.30. 
 
4.2.3.2.1 Cu(II) sarcosyl-L-histidyl-L-lysine complexes 
When the pH was kept constant at 4.5and Cu(II) titrated into the tripeptide solution, some of 
the signals broadened (Figure 4.27).   The C2H a and C5H b resonances of the imidazole are 
shifted upfield after peptide coordination through the N3 nitrogen atom of the imidazole to 
Cu(II).   The higher field chemical shifts for the C2H with respect to the C5H proton result 
from the fact that this proton is closer to the N3 binding center.   In particular, the imidazole 
protons broadened indicates that this group must be coordinating to the Cu(II).   At the same 
time, the lysine amide proton is clearly visible.   This means that this amide is not 
coordinated.   Unfortunately, the absence of the histidine amide cannot be used to infer 
coordination of this group as this amide is also absent in the free ligand spectrum.   The  
Hε-lysine signal f did not broaden indicating that the Cu(II) is not coordinated here.   The 
most predominant species at pH 4.5-5.12 is the CuLH species and so we would postulate that 
in this species, coordination is to the terminal amino-N, imidazole N3 and the histidine amide 
N or amide O.   The stoichiometry supports coordination to the amide O for this species.   
The signals broadened and shifted significantly when the pH was varied and the amount of 
Cu(II) was kept constant.   The shifting is due to the pH change and the broadening is due to 
changes in the Cu(II) coordination.   The spectrum at pH 7.5 shows that the imidazole is 
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coordinated (very little broadening of d and e).   At this pH CuL predominates.   At pH 8.15 
CuLH-1 starts to form and protons d and e broaden substantially.   This implies that the 
terminal amine is now coordinating.   The same applies to CuLH-2 which predominates at  
pH 10.8.  
 
 
Figure 4.27:1H NMR titration for the complexation of Sar-His-Lys (0.075M) with Cu(II) 
(0.0118M) in D2O:H2O 1:9 mixture. Note the break in the f1 dimension at 4.4 ppm. The 
proton assignments are according to Figure 4.15. 
 
4.2.3.2.2 Cu(II) sarcosyl-L-histidyl-L-histidine complexes 
1H NMR results for the complexation of SHH with Cu(II) are given on Figure 4.28.   The 
small amounts of Cu(II) used in the 1H NMR study should enable the observation of 
significant differential broadening of the resonances of protons close to the copper binding. 
At pH 4.10, CuLH is the predominant species in solution.   The overlapping His H-C2 a1, a2 
and H-C5 b1, b2 resonances were both broadened, suggesting that the His imidazole groups 
coordinate to the Cu(II) ion.   The binding of imidazole group nitrogens is common in 
histidine-containing Cu(II) complexes [21,24,29].   Only one His amide proton is observed 




and this broadens with the addition of Cu(II).   This broadening is also attributable to binding 
of the Cu(II).   However, since the amide proton is still observed this amide-N cannot be 
coordinated.   There does not appear to be significant broadening on protons e and f 
indicating that the terminal amine may not be coordinated. 
 
 
Figure 4.28:1H NMR titration for the complexation of Sar-His-His (0.11 M) with Cu(II) 
(0.0118 M) in D2O:H2O 1:9 mixture. Note the break in the f1 dimension at 4.4 ppm. The 
proton assignments are according to Figure 4.18. 
 
When the pH was increased from 4.10 to 7.29, a1, a2 and b1, b2 disappeared almost 
completely implying that the imidazoles are both coordinated.   At pH 7.29, CuL and CuLH-1 
predominate.   At this pH the e and f protons have the same appearance as in the spectra 
without Cu(II).   This implies that the terminal amine is still not coordinated.   At the same 
time the amide protons have disappeared.   However, nothing can be concluded from this as, 
at this pH, amide resonances are in fast exchange with the solvent and so are generally not be 
observed in the 1H NMR spectrum.   At pH 10.6, CuLH-2 predominates but the spectrum 
sharpens and remains sharp irrespective of the amount of Cu(II) added.   This is due to 




chemical exchange as will be explained later.   Hence at this pH the NMR spectrum gives no 
information about the structure of the copper complex. 
 
4.2.3.2.3 Cu(II) sarcosyl-L-lysyl-L-lysine complexes 
The effects of Cu(II) addition on the 1H NMR spectrum of Sar-Lys-Lys are shown in Figure 
4.29.   The addition of small amounts of Cu(II) to tripeptides caused differential broadening 
of resonances, which provided an indication of the location of copper binding.   In the case of 
this peptide we would like to confirm if the C-terminus is coordinated or not.   Comparing 
resonances b1 and b2, b2 is more affected by the Cu(II) and so we postulate that the carboxyl 
of the terminal lysine is coordinated.    
 
 
Figure 4.29:1H NMR titration for the complexation of Sar-Lys-Lys (0.09 M) with Cu(II) 
(0.0118 M) in D2O:H2O 1:9 mixture. Note the break in the f1 dimension at 4.4 ppm. The 
proton assignments are according to Figure 4.21. 
 
CuLH species is the most predominant species at pH 6.13.   At this pH the c and d protons 
are broadened implying that the terminal amine is coordinated.   Note the difference between 




this result and that of the peptides containing a histidine residue.   When the pH was 
increased from 6.13, signal c disappeared.   The stoichiometry supports coordination to the 
N-terminal amine, both amide N’s and the carboxylate O when CuLH-2 forms.   There was no 
significant broadening of the Lys, HƐ a signals in this tripeptide indicating that neither lysine 
side chain amine is coordinated.   Note again that at high pH the spectra become independent 
of the Cu(II) concentration. 
  
4.2.3.2.4 Cu(II) sarcosyl-L-glycyl-L-histidine complexes 
Figure 4.30 shows the effect of Cu(II) ions at different pH values.   The interesting 
observation is that for each of Sar, Gly and His signals there is a characteristic linewidth 
depending on the specific pH value. 
 
 
Figure 4.30:1H NMR titration for the complexation of Sar-Gly-His (0.09 M) with Cu(II) 
(0.0118 M) in D2O:H2O 1:9 mixture. Note the break in the f1 dimension at 4.4 ppm. The 
proton assignments are according to Figure 4.24. 
 
CuLH is the predominant species at pH 4.3.   The broadening of signals a, b and c indicate 
coordination to the imidazole N.   The resonances d and e1, are affected by the Cu(II) and so 




we postulate that the amide N or amide O is coordinated.   The stoichiometry supports 
coordination to the amide O for this species.   At pH 5.39 CuLH-1, predominant species and 
protons e2 and f broaden substantially.   This implies that the terminal amine is now 
coordinating.   The same applies to CuLH-2 which predominates at pH 9.71.   In strongly basic 
conditions, all the signals appear again and sharpen. 
 
4.2.4 Discussion 
The structure of Cu(II) complexes with tripeptide were studied by 1H NMR. The possible 
binding sites for these tripeptides are the imidazole nitrogen, the amide nitrogen or amide 
oxygen, the N-terminal nitrogen (-NH) and C-terminal oxygen (COO-).   The 1H NMR 
spectra were recorded at various pH values, where the maximum concentrations of the 
various species are observed, as deduced from the speciation diagram.   From the chemical 
shifts of Cu(II) complexes with Sar-His-Lys, Sar-His-His and Sar-Gly-His the imidazole ring 
of the histidine residue, with its two N3 and N1 nitrogen atoms, has been shown to be a good 
metal-binding site in the reaction of histidine-containing peptides with Cu(II) complexes.   It 
is well known that Cu(II) anchored to the N3 nitrogen atom in the histidine side chain is 
highly effective in displacing the amide proton and forms very a stable six-membered chelate 
ring [23-25,49]. 
 
The Cu(II) Sar-His-His and Sar-Gly-His complexes where a [-NH, N-, N-, Nim] donor set was 
reported in basic pH, the third equatorial position is occupied by the C-terminal imidazole 
nitrogen.   Unfortunately, the 1H NMR experiments did not give precise information on the 
conformation adopted by the tripeptides [29].   Resonances assigned to the ԑ-amino group of 
lysine were relatively unaffected by copper addition, indicating that lysine does not 
coordinate to the Cu(II) [50]. 
Finally, in strongly basic conditions, all the signals appear again and sharpen when the pH 
rises.   Recently, a similar observation has also been made with a cyclic peptide [51] and a 
linear peptide [52].   Since in solution, the concentration of the ligand is very much greater 
than that of Cu(II),  the effect of Cu(II) coordination is transferred to the bulk free ligand via 
chemical exchange.   The sharpening of the signals with increasing pH is explained by the 
slowing down of the exchange [52-54]. 
 
 




4.3 ELECTROSPRAY IONISATION MASS SPECTROMETRY 
4.3.1 Introduction 
Quantitative bonding studies are necessary in order to determine the affinity of the copper 
compounds to amino acids, tripeptides and proteins.   The influence of varied concentrations 
of the reactants on the observed interactions can provide valuable information regarding the 
association constants [55].   The complex of copper species with tripeptides and proteins that 
are now described for the synthetic solutions must be investigated in real biological samples. 
Electrospray ionization mass spectrometry (ESI-MS) has been widely used for the 
characterization of a wide variety of inorganic complexes in the gaseous phase [56].   ESI-
MS is an extremely important tool for studying molecular weights and structures of metal 
complexes [57,58]. Moreover, it has been used to provide both qualitative (structure) and 
quantitative (molecular mass or concentration) information on analyte molecules after their 
conversion to ions [59].   In this study, ESI-MS was used to obtain information about the 
molecular mass of the metal complex species so as to confirm the assumed structures from 
potentiometric and spectroscopic studies.   In addition, fragmentation patterns from ESI-MS 
may provide more structural information.   By studying Cu(II) tripeptide species as a function 
of pH, it was possible to observe the appearance of all species in solution that are dependent 
on pH.   As in potentiometry, Cu(II) and tripeptide concentrations and ratios were used for 
ESI-MS experiments in order to facilitate the detection of all possible Cu(II) complex species 
observed in the same pH range. 
4.3.2 Experimental 
ESI-MS spectra were recorded on Agilent 6120 Quadruple LC/MS system with ESI resource.   
ESI-MS spectra were acquired in the 1500 amu region using 20 ms dwell time.   An ion spray 
voltage of 4000V was applied in positive ion mode [55].   The orifice potential of 70V was 
established as offering the best signal intensity causing partial fragmentation of the  
tripeptide [60].   The Cu(II) complex solutions were prepared by dissolving the tripeptide and 
Cu(II) in water at 1:1 ratio with the concentration of tripeptide 0.005 M.   The solutions were 
investigated in the pH range 3.04-10.22 where the pH values were adjusted with HCl or 
NaOH.  
 




4.3.3 Results and Discussion 
The mass spectra of the Cu(II) complexes of Sar-His-Lys are shown in Figures 4.31 and 4.32.   
From this, it is clear that fragmentation of the complex has taken place with the peak at 
m/z = 355.2 due to the free Sar-His-Lys.   Using the isotopic ratio of 63Cu (69%) and 65Cu 
(31%) it is possible to identify peaks due to the complex.   The spectra relative to the ion 
present shows successive loss of water molecules.   Presented in Table 4.10 are ions 
registered in positive ions mode (PIM)  in mass spectra of solutions of the SHK-Cu 
complexes in the pH range 3.04-10.22 [61].  
Table 4.10: Ionized species observed in ESI-MS of Cu-SHK. 


























In the mass spectrometric investigations various interactions of copper with Sar-His-Lys  
were found.   The peak corresponding to the [CuSHK.(H2O)n] complex appeared 
simultaneously with the peak of the free SHK in the ESI-MS spectra.   Solvent adducts very 
often form under ESI-MS conditions, due mainly to coordination with the metal center.   The 
formation of pseudomolecular or adduct ions (Na+ and Cl-) during ESI-MS is very common.   
These adducts almost never exist at equilibrium but they are artefacts of ESI.   As before, the 
stoichiometric recognition of the species in solution is not impaired but may become more 
difficult [62].   Although ESI does result in fragmentation polymerization is sometimes 
observed both for free and bound ligand molecules and depending on the extent of this 
phenomena, the recognition of all peaks may become more difficult or even impossible, thus 
impairing the analysis [63].   However, the addition or loss of a proton is a very quick 
process.   Therefore, ESI-MS is not able to individuate the ionizable proton content of the 
species, regardless of the kinetic properties of the metal–ligand displacements.   Generally, 
only one [CuSHK.(H2O)n] peak was detected by ESI-MS, while different number of water 




molecules were expected in solution.   This, of course, must be considered as an intrinsic 
limitation of ESI, and cannot be overcome.   Moreover, it may also represent an advantage 
because the addition and/or loss of protons allow the detection of neutral species [64]. 
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Cu-SHKL1 at pH 8.27 





Figure 4.32: Mass spectra of the solutions of Cu-SHK species in the range pH 9.22-10.22. 
 
ESI-MS spectra are from moderate to very sensitive to the instrumental parameters 
employed, such as spray voltage, capillary temperature, capillary voltage, tube lens offset, 
and especially cone voltage [65].   In addition, different chemical species usually have 
different response factors due to the different efficiency of the processes which lead to the 
production of gas-phase ions from the species in solution [66,67].   Although, the ESI-MS 
technique showed that complexation of Cu(II) with Sar-His-Lys occurred it was not possible 
to assign peaks to specific species to show speciation of Cu(II) at different pH values using 
this technique.   Thus, the identity and speciation of the Cu(II) complexes could not be 
compared with those obtained from the potentiometric and spectroscopic studies.   
 
4.3.4 Conclusion 
In this study, we explored the potential application of ESI-MS for probing the interactions of 
Cu(II) ion with tripeptide.   The effect of pH on the formation of Cu(II) tripeptide complex 
species was not observed.   Therefore, the ESI-MS technique did not provided useful 
information on the structures of the Cu(II) tripeptide complex species.   Thus, further work is 
needed to explore the sensitivity and resolution of the mass spectrometer and also investigate 
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4.4 MOLECULAR MECHANICS 
4.4.1 Introduction 
Computer modelling is now widely used as an aid in the interpretation of experimental results 
and in the design of new materials with desirable properties.   Its wide use is primarily due to 
its computational simplicity and efficiency.   Quantum mechanical modelling, however, is far 
more computationally intensive than other computer modelling programs and until recently 
has been used only for a few metal complexes [68,69].   Molecular mechanics (MM) is a 
model that has been developed out of a need to describe molecular structures and properties 
in a practical manner [70,71].   The strain energy calculations of a molecule are done using 
force fields, but the choice of which force fields to use in a calculation is entirely dependent 
on the type of complex or molecule (i.e. organic or inorganic) of interest and the software 
program used to run the simulation [72].   In addition, there are a limited number of reliable 
force fields to use for the MM calculation involving metal ions.   Therefore, MM calculations 
involving transition metal ions are not done to the same extent as organic molecules [73,74]. 
 
4.4.2 Theory 
The structures are built using molecular orbital and valance bond theories.   Their 
conformation is optimised using force fields where the strain energy (E) of these structures is 
calculated.   The basis of the molecular mechanics method is that a good estimate of the 
geometry of a molecule can be obtained by taking into account all the forces between atoms 
and calculated using a mechanical approach.  
The geometry is optimised such that the total bond deformation strain (Eb), the total steric 
strain/van der Waals strain (Es), the angle strain (Ea), and the torsional strain (Et) are 
minimised.   The total strain energy (Etot) can therefore be expressed as; 
                                         Etot = Eb + Es + Ea + Et                                                          (4.5) 
The individual energy terms are calculated using simple functions with bonds modelled as 
springs that obey Hooke's law [75]; 




2                                                        (4.6) 




where k1 is the force constant or spring strength and l is the bond length when the structure is 
deformed and l0 is the length of the bond when the structure is at equilibrium.   Eb can also be 
expressed in terms of the Morse function [76,77]; 
                                        Eb = ∑ Dbbonds (1 − e−a(l−l0))2                                                (4.7) 
The steric/van der Waals strain is the strain experienced by a molecule that has non-bonded 
electrons from different substituents that repel each other.   Rappé and co-workers [78] have 
derived an equation for calculating total steric strain as: 












6]                            (4.8) 
where DIJ is the finite energy for breaking bonds, xIJ is the van der Waals bond length, x is the 
atomic van der Waals distance, and ζ is the shape factor. 
The angle deformations can also be estimated using Hooke’s law. 




2                                                        (4.9) 
where kb is the force constant for a particular angle, b is the bond angle when the structure is 
deformed and b0 is the bond angle when the structure is at equilibrium. 
Torsional strain is experienced when a molecule undergoes a complete rotation around one 
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where V1 is a term assigned to van der Waals interactions/residual dipole-dipole interactions, 
V2 is a term assigned to conjugation/hyper-conjugation and V3 is assigned to steric or 
bonding/anti-bonding interactions.   The geometry of the copper complexes was optimized 
using different force fields.   The generic force field, extensible systematic force field (esff) 
which requires atomic coordinates and the force field parameters, including partial charges, 
were used as input [76].  
The advantage of esff is its capability to model most of the elements of the periodic table. 
Esff employs semi-empirical rules to translate atomic-based parameters to parameters 
typically associated with a covalent valence force field. In general, force field terms are 




derived empirically with the target of reproducing experimental structures and energy 
distributions [69,79,80].   However, the goal of molecular mechanics is to find the geometry 
with minimum strain energy. The force field has been applied to molecular simulations of  
a wide variety of systems including nucleic acids, peptides, hydrocarbons, porphyrins, 
transition metal complexes, zeolites and organometallic compounds.  
 
4.4.3 Simulation 
The chemical and physical understanding of copper tripeptide species gained through 
simulation will be directly applicable to combined molecular orbital and empirical energy 
function calculations planned to examine the detailed interaction of molecular mechanics 
with electronic structure [81,82].   The esff force field was used in the MM simulations. The 
different chemical species in solution were constructed using the BUILD module of the 
Accelrys Biosym/MSI software package and were based on the speciation models  
obtained from Uv-Vis spectroscopy and potentiometry studies.   Geometry optimization and 
energy calculations were performed using the Discover_3 program which was run as an 
application in the Insight II package [83].  
 
4.4.4 Results and Discussion 
The output data for internal energy (Eint), bond (Eb), angle (Ea), torsion (Et) and out-of-plane 
(EOop) deformation energies (kcal mol-1) of different proposed species are given in  
Table 4.11.   The system makes many changes in the atom position through rotation and 
calculates energy in every position.   This process is repeated several times to find the best 
position with minimum energy [84,85]. 
Table 4.11: Internal energy (Eint), bond (Eb), angle (Ea), torsion (Et) and out-of-plane (EOop) 
deformation energies (kcal mol-1) of different Cu(II) tripeptide complex species present in 
solution. 
 A B C D E F 
-NH, CO, Nim, H2O -NH, N-, Nim, H2O -NH, 2N-, Nim -NH, N-, 2H2O -NH, 2N-, COO- NH, 2N-, Nim, (Nim) 
Eint 32.93 14.16 22.71 11.60 26.71 105.70 
Bond 01.54 00.68 01.54 02.68 03.21 7.14 
Angle 25.33 09.14 13.26 06.53 16.77 50.66 
Torsion 05.85 04.24 07.24 02.24 06.26 44.67 
Oop 00.22 0.10 00.67 00.15 00.48 3.24 
 




The energy minimised Cu(II) complexes of different proposed species present in solution are 
shown in Figure 4.33.   Molecular mechanics (MM) has been considered here as a method for 
calculation of molecular structures, conformational energy minimised and support of the 
solution structures postulated from potentiometric and spectroscopic data.   In this regard, 
some structures of species postulated from both potentiometry and spectroscopy have been 
considered for each Cu(II) tripeptide species.  
Figure 4.33: Energy minimised Cu(II) complexes of different proposed species present in 
solution.    A: Energy minimised Cu(II) complexes showing the coordination by an amino 
nitrogen, a carbonyl oxygen and an imidazole nitrogen donor atoms, giving a 5,8 chelate ring 
sequence (32.93 kcal mol-1) for the CuSHK-H, CuSHH-H and CuSHH species. 
 
 
B: Energy minimised Cu(II) complexes showing the coordination by an amino, an amide and 
an imidazole nitrogens donor, giving a 5,6 chelate ring sequence (14.6 kcal mol-1) for the 
CuSHK, CuSHK-H-1, CuSHK-H-2 and CuSHH-H-1 species. 
 




C: Energy minimised Cu(II) complexes showing the coordination by an amino, two amides 
and an imidazole nitrogens donor, giving a 5,5,6 chelate ring sequence 




D: Energy minimised Cu(II) complexes showing the coordination by an amino and an amide 








E: Energy minimised Cu(II) complexes showing the coordination by an amino, two amide 
nitrogens and carboxylate oxygen donor, giving a 5,5,5 chelate ring sequence  
(26.71 kcal mol-1) for the CuSKK, CuSKK-H-1 and CuSKK-H-2 species. 
 
 
F: Energy minimised Cu(II) complexes showing the coordination by an amino, two amides 
and an imidazole nitrogens in equatorial and axial of imidazole nitrogen donor in position II, 
giving a highly strained (105.76 kcal mol-1) for the CuSHH-H-1 and CuSHH-H-2 species. 
 
 
The results from stability constant determination indicated that the complexes are quite stable 
under biological conditions.   The obtained binding energies for the Cu(II) species 




coordinated to each of these tripeptides were very similar and not very far from those 
determined for the N-terminal metal binding site of the protein, attesting to the high stability 
of copper when inserted into this kind of environment [86].   The presence of six-membered 
chelates in internal or C-terminal positions of fused chelate rings generally enhances the 
thermodynamic stability of peptide complexes, while if they are in N-terminal position, the 
metal binding affinity is significantly reduced [33].   Angular distortions in the square plane 
are also caused by the different bite angles in the five- and six- membered chelate rings.   The 
distortion of the structures from square planar to tetrahedral can be evaluated through the 
parameter Δ introduced by Galy et al. [87] and applied by Ribas and Kahn [88]. 
The other source of strain contribution to the differences in stability is the energy associated 
with torsion of bonds as the different donor atoms are oriented for coordination to the metal 
ion. Bond stretching seems to have less significant contribution to the differences in strain 
energies of these structures.   Most differences in internal energy contribution arises from 
twisting of bonds and bending of angles as coordinating atoms are accommodated around the 
central metal ion.  
In all calculations, electronic contributions, ie Jahn-Teller distortion are not taken into 
account. Nor are entropy effects, both in terms of chelate effect of the ligand and  
solvent [89,90].   In addition, the bond formation energies were not taken into account, but 
only the contribution of their distortion from ideality was considered.   
The proposed structure for the CuSHK-H, CuSHH-H and CuSHH species is given in  
Figure 4.33(A).   The 1H NMR study showed that the imidazole nitrogen is coordinated at the 
beginning of complexation.   It was also shown that the structures involving carbonyl oxygen 
donor atoms which coordinated to the metal ion are relatively more strained.   The rigidity of 
the imidazole moiety seems to contribute to the strain energy when the carbonyl oxygen 
donor atom is coordinated to the metal ion.   Therefore, the strain energy of these structures 
arises from both the sequence and the size of the rings formed around the metal ion upon 
different donor atom coordination.   However, the 5,8 structure (A) had a high angle bending 
energy (25.33 kcal mol-1) and torsion energy (5.85 kcal mol-1).   This came about because the 
planarity of the amide group has been compromised.    It was expected that as the pH 
increased, Cu(II) would induce ionization of the amide proton and there would also be a 
transition from Cu-O to Cu-N coordination [91,92].   In structure (B), the amide coordination 




was likely due to the close proximity of the metal ion enhanced by the coordination of an 
amino, an amide and an imidazole nitrogens donor for the CuSHK, CuSHK-H-1, CuSHK-H-2 
and CuSHH-H-1 species.   The result of energy minimized structures showed that the 5,6 
chelate structure (B) has a slightly lower internal energy.   The main contribution to the 
internal energy is from the angle strain which is generated when forming the 6 membered 
rings.  
An alternative structure (C), is where an amino, two amides and an imidazole nitrogen donor 
are coordinated to the Cu(II) ion forming a 5,5,6 chelate rings sequence (22.71 kcal mol-1).   
Based on the MM calculations, it can be seen that the tripeptide is not a tetradentate ligand, 
but behaves as a tridentate ligand.   In terms of the internal energies of the structure (C), a 
5,5,6 chelate structure had a considerably low strain energy (22.71 kcal mol-1) and there was 
a slightly high angle bending energy.   The coordination of the imidazole nitrogen donor atom 
is likely to occur once the amino and two amidic groups are coordinated.   Moreover, the 
coordination of the two deprotonated amide groups ensures planarity of these groups, 
resulting in restriction on the chelate geometry [93].   From the potentiometric and 
 Uv-Vis spectroscopy data a similar solution structure was postulated as predicted by the MM 
calculations with a λmax value of 530 nm.   This value clearly suggests a square planar 
geometry for the CuLH-1 and CuLH-2 species of the Cu(II) Sar-Lys-His, Cu(II) Sar-His-His 
and Cu(II) Sar-Gly-His complexes.   These MM calculations give extra experimental 
evidence in support of this geometry.   Structure (D) was chosen as the most likely 
representative structure for the coordination by an amino and an amide nitrogens donor, 
giving a 5 chelate ring sequence (11.60 kcal mol-1) for the CuSKK-H species.   This is 
consistent with the structure proposed from the Uv-Vis spectroscopy study.   Despite a high 
torsion energy in the 5,5,5 chelate structure (E), formation of the 5,5,5 chelate ring is more 
probable because of the close proximity of the second coordinating amide nitrogen donor in 
the coordination sphere.   The 5,5,5 chelate structure supported by MM calculations has also 
been postulated from potentiometric data and this therefore, lends confidence to the presence 
of this species in solution for the CuSKK, CuSKK-H-1 and CuSKK-H-2 species.    
Structure (F) has a weakly bound axial coordination of imidazole ring in position II.   
However, the major contribution to the internal strain energy comes from the bend angle 
(50.66 kcal mol-1) and torsion angle (44.67 kcal mol-1) energies, as well as the effect of the 
bonds on the axial ligands which distorts the octahedral geometry of Cu(II) complexes.   




In general, the distances to the axial ligands are longer than to the equatorial, but also 
shortening of the axial bonds has been observed.    In addition, the structure (F) of the CuLH-2 
species in Sar-His-His is likely to be overall octahedral with a weak axial imidazole nitrogen 
donor, which are not observed in the Uv-vis spectroscopic.    
The λmax was observed at 520 nm for CuLH-2 of the Sar-His-His.   This value corresponds to 
a square planar geometry with one amine, two amides and an imidazole nitrogen donor in 
equatorial positions.   Similar λmax values of CuLH-2 with Sar-Lys-His and Sar-Gly-His were 
observed, when the axial imidazole in position II did not exist.   Moreover, the coordination 
of the two deprotonated amide groups ensures planarity of these groups, resulting in 
restriction on the chelate geometry.   The MM calculation gives extra experimental evidence 
in support of a square planar geometry.   Such a result clearly demonstrates the limitations of 
MM calculations as a computational tool for Cu(II) complex species since it does not account 
for electronic contributions of the metal or entropy effects, both in terms of the chelate effect 
of the ligand and the solvent.  
 
4.5 GENERAL CONCLUSIONS 
The structural variety of the Cu(II) complex formation processes of tripeptides comes from 
a large number and many different arrangements of donor atoms both in the backbone and the 
side chains of the molecules.   In the present study, by using potentiometry, spectroscopy and 
molecular mechanics different binding sites for Cu(II) tripeptide species were observed.   The 
geometrical structure of species gave the square planar shape for tripeptides having His at 
position II (Sar-His-Lys) in the formation of 3N [-NH, N‒, Nim].   The square planar shape 
was also observed for tripeptides having His at position III (Sar-Lys-His & Sar-Gly-His) in 
the formation of 4N [-NH, N‒, N‒, Nim] and tripeptide that does not have His (Sar-Lys-Lys) in 
the formation of 3N [-NH, N‒, N‒, COO‒].   In addition, with the exception of Sar-His-His, 
Uv-vis spectroscopic and MM calculations suggest a weak axial coordination of imidazole 
ring.   In contrast, the same ring remained uncoordinated in the case of the NiLH-2 species 
with Sar-His-His.   A possible participation of the ԑ-amino group of the Lys residue in the 
coordination sphere of metal ions was not observed, although its deprotonation of MLH-1 led 
to MLH-2 species which are the same protonation of the ԑ-amino group of the Lys residue in 
free tripeptides. 
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5.1 BLOOD PLASMA MODEL 
5.1.1 Introduction 
The nutritional and pharmacological activity of trace metals has been reported extensively in 
the literature [1].    It has also been well demonstrated that Cu(II) complexes are effective in 
treating inflammation associated with rheumatoid arthritis.   This pharmacological effect was 
first associated with the concentration of the free labile copper (II) in the body.   Sorenson 
reported that the active forms of anti-inflammatory drugs may well be the Cu(II) complexes 
of such drugs in vivo [2].   
The chemical analysis of all the metal species present in a complex solution like blood 
plasma is not really possible.   However, assuming that the system is at equilibrium, a 
computer model can be used to calculate this speciation [3].   The Evaluation of Constituent 
Concentrations in Large Equilibrium Systems  (ECCLES) program [4] and its associated 
database is able to do this.  Therefore, the focus of this study was to investigate the efficiency 
of tripeptides (drug) in mobilising copper in vivo using the plasma modelling program 
ECCLES [4].   
In this context, mobilization is defined as the ability of the ligand/drug to increase the 
concentration of low molecular weight (l.m.w) species in plasma.   Numerically this is given 
by the plasma mobilizing index (p.m.i), which the ratio of the l.m.w.   Cu(II) concentration in 
the absence of the ligand/drug to the concentration in the presence of the drug/ligand.   In 
calculating p.m.i., Cu(II) complexation with endogenous ligands as well as complexation of 
the ligand by endogenous metal ions is taken into account.   In other words, the specificity 
and strength of Cu(II) chelation is taken into account.   A strong specific Cu(II) chelator 
would a have high p.m.i value at low drug concentrations, indicating a potentially useful 
therapeutic agent. 
 
5.1.2 Data Analysis 
The ECCLES database consists of 7 metal ions, 40 ligands, 250 published mononuclear 
binary constants measured under physiological conditions, with another 400 measured under 
non-physiological condition and 100 ternary complex constants [5,6].   The stability constants 
of H+, Cu(II), Ni(II) and Zn(II) complexes of the tripeptides (drugs) measured in this study 
were added to the ECCLES database so as to calculate their plasma mobilizing indices.   The 
total ligand concentration was varied over the range 10-1- 10-10 M at constant pH of 7.40.  




In the blood plasma model, Ca(II) is in high concentration and even though its metal 
complexes are likely to be much weaker than Cu(II), because it is in such high concentration 
it may interfere with the Cu(II) binding.   For this reason it is important to include the Ca(II) 
tetrapeptide stability constants in the model.   Unfortunately these were not measured in this 
study but their values can be estimated from linear free energy relationships [7,8].   Figure 
5.0 shows the linear free energy relationship between Ca(II) and Cu(II).   A regression 
coefficient of 0.9 was obtained and from this the stability of the Ca(II) complexes of the 
tripeptides were estimated (Table 5.0).    
Table 5.0: Database of the linear free energy relationship between Ca(II) and Cu(II). 
 
Ligand Species  Ca(II) Cu(II) 
GLY-GLY 
Glycylglycine 
ML 2.04 5.62 
HIS 
Histidine  
ML2H 15.4 21.82 
 MLH 9.35 12.88 
 ML 0.95 9.56 
ASP 
Aspartic acid 
ML 1.6 8.83 
ALA 
Alanine 
ML 1.24 8.14 
B-ALA 
Beta-alanine 
ML 1.639 6.99 
    
3-Phos-ALA 
3-phos-alanine 
ML 1.82 9.6 
D-GLA 
D- Glutamic acid 
MLH-1 -10.15 -2.6 
2-OxOsuccinic acid ML 2.6 4.22 
bis(imidzol-2-yl)methane ML 1.8 9.64 




MLH 18.27 28.29 
 MLH2 23.83 31.95 
 M2L 13.23 28.15 




MLH 15.48 23.3 
 MLH2 21.03 25.9 
 M2L 11.62 24.1 
H5dtpa 
1,4,7-triazaheptane-1,1,4,7,7-pentaacetic acid 
ML 10.75 21.2 
 MLH 16.86 26 




The stability of Ca(II) MLH-1 and MLH-2 species were not calculated as Ca(II) only 
coordinates to the oxygen donors of the peptide [9,10].   There is exception to this, where the 
metal coordinates to the imidazole nitrogen, but this only happens at pH 7.0 [11,12]. 
 
 
Figure 5.0: Linear free energy relationships between logβ Cu(II) and logβ Ca(II) of amino 
acid and peptides complex species at the same ionic strength and temperature.   Data were 




The p.m.i, as a function of the ligand concentration is given in Figure 5.1.   A log p.m.i. of 1 
means a 10 fold increase in the l.m.w.    
 
Figure 5.1: log p.m.i as a function of log [Sar-His-Lys] for Cu(II), Ni(II), Zn(II) & Ca(II) 
complexes. 
y = 0.8237x - 4.9678 
 






































At low ligand concentrations, between 10-6 and 10-5 M, Sar-His-Lys was able to mobilise 




Log p.m.i curves for Sar-Lys-His are given in Figure 5.2.   At ligand concentrations above  
10-5 M, Sar-Lys-His mobilised Cu(II) more than Ni(II), Zn(II) and Ca(II). 
 
 
Figure 5.2: log p.m.i as a function of log [Sar-Lys-His] for Cu(II), Ni(II), Zn(II) & Ca(II) 
complexes.  
 
5.1.3.3 Sar-His-His  
 






































Log p.m.i for complexes of Sar-His-His with Cu(II), Ni(II), Zn(II) and Ca(II) are shown in 
Figure 5.3.   Sar-His-His mobilised Cu(II) more than Ca(II), Zn(II) and Ni(II) in blood 
plasma at concentrations of ligand above 10-4 M. 
 
5.1.3.4 Sar-Lys-Lys 
The log p.m.i curves for Sar-Lys-Lys with Cu(II), Ni(II), Zn(II) and Ca(II) complexes are 
shown in Figure 5.4.   This ligand mobilised Zn(II) over Cu(II) and Ca(II) at concentrations 
of 0.1 M.   Therefore, this ligand was not able to mobilise copper in vivo. 
 
 











































Figure 5.5 shows log p.m.i curves for Cu(II), Ni(II), Zn(II) and Ca(II) plotted against the 
concentration of Sar-Gly-His.   It was able to cause a more than 10 fold increase in l.m.w 
Cu(II) concentration at a total ligand concentration of 10-4 M. 
 
5.1.4 Discussions 
For any ligand metal system, a high log pmi value at low ligand concentration indicates that 
the ligand is a good competitor against other potential ligands present in the blood  
plasma [15].   Figure 5.6 shows log p.m.i of different tripeptides in this study complexed with 
copper as a function of tripeptide concentration.   The Cu(II) mobilising ability was in the 
order of Sar-Lys-His > Sar-Gly-His ≈ Sar-His-His ≈ Sar-His-Lys > Sar-Lys-Lys.  
Sar-Lys-Lys was not able to mobilise copper in vivo.   The reason for this is the relatively 
high affinity of Sar-Lys-Lys for Zn(II).   The lack of an imidazole group this ligand means 
that it is not as selective for copper.   With the high in vivo concentration of Zn(II), Cu(II) is 
not able to compete effectively.   Although it has been reported that tripeptides containing an 
imidazole residue are not particularly good at mobilising Cu(II) in vivo [16], it seems the 
better mobilisation arising from Sar-Lys-His, Sar-Gly-His, Sar-His-His, Sar-His-Lys as 
opposed to Sar-Lys-Lys are as a result of the high basicity of the imine nitrogen of the 
imidazole ring with a reported pKa value of 6.95 [17,18].   However better mobilisation of 
Cu(II) as compared to Ni(II), Ca(II) and Zn(II) could be due to the preferential binding of 
ligands to Cu(II) compared to Ni(II), Ca(II) and Zn(II).    
Poor mobilisation of Ni(II) was observed in this study even though Ni(II) formed more stable 
complexes compared to Zn(II) and Ca(II).   In vivo, the free concentrations of Ca(II) and 
Zn(II) are 1015 and 109 times greater than the free concentration of Ni(II) and this higher 
concentration means that they are able to displace Ni(II) from its complexes [19].  
The p.m.i curves of different tripeptides and triethylenetetramine TRIEN [20,21] are shown 
in Figure 5.6.   In comparison, TRIEN is six to three orders of magnitude better at mobilizing 
Cu(II) in vivo than Sar-Lys-His, Sar-Gly-His, Sar-His-His and Sar-His-Lys.   The improved 
mobilizing ability of TRIEN compared to these tripeptides is related to the stable Cu(II) 
complexes of TRIEN and weak Ca(II) binding.   This is also shown by EDTA, which is a 
poor mobiliser of Cu(II) even though it form very stable complexes.   For EDTA the Ca(II) 
complex is also very stable. 






Figure 5.6: Plasma mobilising index for Cu(II) with tripeptide and TRIEN complexes. 
 
In summary, the results show that, with the exception of Sar-Lys-Lys, all the tripeptides are 
predicted to mobilise Cu(II).   At the same time, however, the speciation of Ca(II) is also 
effected.   This is an unwanted side effect and is a result of the higher than anticipated 
stability of the Ca(II) complexes.   As these stability constants were only estimated it is 



































5.2 OCTANOL / WATER PARTITION COEFFICIENTS 
5.2.1 Introduction 
Cu(II) complexes can be administered orally or by injection either intravenously or 
intraperitoneally.   Although these two methods allow easy drug administration to increase 
the available Cu(II), it is difficult to move the coordinated metal across body compartments 
without protein binding [22].   The usefulness of a procedure in drug administration depends 
on the lipophilicity and molecular weight of the drug [23,24].   Partition coefficient 
measurements can be used as a reference parameter for hydrophobicity in biochemical and 
pharmacological systems.   This is a powerful tool in estimating the tissue permeability of 
drugs. The partition coefficient between octanol and water is defined as: 
                                      log 𝑃oct\aq = log (
[Cu(II)]oct   
[Cu(II)]aq)
)                                                         (5.1) 
where [Cu(II)]oct is the amount of Cu(II) extracted into octanol and [Cu(II)]aq is the amount of 
Cu(II) left in the water phase.   The amount of Cu(II) transferred from aqueous solution to 
organic layer changes with pH because speciation changes with pH and the different species 
have different partition coefficients.   This study seeks a viable transdermal alternative of 
copper with tripeptide as a therapy for inflammatory disorders and therefore the degree of 
lipophilicity is important. 
 
5.2.2 Experimental 
The Shake Flask method was used to measure partition coefficients where the organic phase 
was 1-octanol pre-saturated with water [25].   Standard solutions of Cu(II) were prepared as 
described [15,26,27].   Copper to tripeptide solutions, at a ratio of 1:1, were prepared in 
distilled/deionised water (0.005 M).   5 ml aliquots of 1:1 Cu(II): tripeptide solutions, in the 
pH range 2.00 – 11.00, into 10 glass vials were dispersed.   6 ml of 1-octanol (99 %) was 
added into each solution.   The mixture was then shaken for two minutes and left for five 
minutes so that the two phases could separate at a constant temperature of 25 °C.   To 
determine Cu(II) in the organic phase, 5 ml aliquots were withdrawn and extracted back into 
an aqueous phase with  6 ml of 5 % HNO3.   4 ml aliquots were then withdrawn from the new 
aqueous phase (5 % HNO3).   The concentration of copper in each phase was measured using 
Microwave Plasma-Atomic Emission Spectrometry (MP-AES).   The measure of 
hydrophobicity can be expressed as the logarithm of the partition coefficient between  




l-octanol and an aqueous phase.   The partition coefficients of Cu(II)-complex as a drug were 
calculated using Equation 5.1. 
 
5.2.3 Results 
5.2.3.1 Cu(II) Sar-His-Lys 
The results for Cu(II) Sar-His-Lys are shown in Figure 5.7, which shows the log Poct\aq results 
and the speciation graph for Cu(II) Sar-His-Lys as a function of pH. The Cu(II) complexes of 
Sar-His-Lys were more soluble in water than in 1-octanol, as is shown by the negative values 
of  log Poct\aq.   The partition coefficients changed as the pH increased due to the formation of 
various species.   Comparison of the speciation diagram and the log Poct\aq curve is interesting 
as it clearly shows how the partition coefficient changes as the CuL species is formed and 




Figure 5.7: Log Poct\aq and speciation graph as a function of pH for 1:1 Cu(II):SHK system.  
 
5.2.3.2 Cu(II) Sar-Lys-His 
Results for Cu(II) Sar-Lys-His are presented in Figure 5.8.   The solubility in 1-octanol 
increased from low pH to pH 7.07.   At physiological pH, CuLH-1 was the predominant 
Cu(II) species at 97 %.   At this pH, only 0.88 % of the Cu(II) was extracted into the organic 
































having a negative log Poct\aq value.   At pH 10.4, CuLH-2 was the most predominant species 
with a log Poct\aq value of ~-2.79. 
 
Figure 5.8: Log Poct\aq and speciation graph as a function of pH for 1:1 Cu(II):SKH system.  
 
5.2.3.3 Cu(II) Sar-His-His 
The negative values of log Poct\aq for Cu(II) Sar-His-His show that this complex is largely 
hydrophilic (Figure 5.9).   The partition coefficient profile is quite complex in that it 
increases, decreases and then increases again.     This profile, however, is easily rationalised 
by reference to the speciation diagram. At pH 4.13, the most predominant species was CuLH, 
with a log Poct\aq = -2.43; at pH 7.43 the most predominant species was CuLH-1, with a log 
Poct\aq = -2.9 and at pH 10.05 the most predominant species was CuLH-2, with a log Poct\aq = 
-2.74. 
 




























































5.2.3.4 Cu(II) Sar-Lys-Lys 
Results for Cu(II) Sar-Lys-Lys are given in Figure 5.10.   The solubility in 1-octanol 
increased from low to high pH.   There was a rapid increase in log Poct\aq values as the pH 
increased from 6.15-11.10 due to the formation of CuL (95.67 %) with maximum log Poct\aq 
values of -2.6.   The relatively hydrophilicity of this species in addition to the charge 
distributions, explains the preference of the complexes for the aqueous layer resulting in 
negative values of log Poct\aq. 
 
Figure 5.10: Log Poct\aq and speciation graph as a function of pH for1:1 Cu(II):SKK system. 
 
5.2.3.5 Cu(II) Sar-Gly-His 
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The results for Cu(II) Sar-Gly-His are given in Figure 5.11.   The CuLH species was the 
predominant species at pH 4.56, where the log Poct\aq was -3.34.   At pH 6.48, the log Poct\aq 
values of Cu(II) Sar-Gly-His was -1.91 and the CuLH-2 species was predominant at this pH. 
There was an increase in log Poct\aq values from pH 2.52 to 6.48, where upon it decreased. 
This partition coefficient profile does not exactly match the species distribution curves. The 
explanation for these observations is that the MLH-2 species has a higher partition coefficient 




The log Poct\aq values for complexes of Cu(II) with different tripeptides at pH 7.4 is given in 
Table 5.1.   With the exception of the Sar-Lys-Lys and Sar-Gly-His systems, where there is 
some discrepancy, the partition coefficient curves mirror the change in speciation with pH.    
This is satisfactory since the two parameters were measured independently.   Novel Cu(II)-
based anti-inflammatory drugs with log Poct\aq above zero at a physiological pH of 7.4 have 
been reported [3].   All four tripeptides increased the lipophilicity of the Cu(II) but all the 
complexes were hydrophobic, with a negative log Poct\aq.    Deprotonation of the ligand does 
improve the lipophilicity as does N-methyl substituent on the terminal amine.  
 
Table 5.1: Log Poct\aq’s for Cu(II) complexes with different tripeptides at pH 7.4. 
 


























Previous studies showed that complexes with log Poct\aq < 2.5 are considered to have low 
lipophilicity whereas, those with log Poct\aq > 5 are believed to have high lipophilicity.    
Furthermore, complexes with log Poct\aq between 2.5 and 5 are considered to have 
intermediate lipophilicity [28].   The lipophilicity of complex species improves with an 
increase in pH, except in systems where Cu(II) precipitates out when excess amounts of 
NaOH are added.   Zvimba and Jackson, however, suggest that the log Poct\aq of 0.60 is 
sufficient enough to allow trans-dermal transportation of drugs [29].   In fact compounds that 




are too lipophilic are poorly absorbed through the skin as they become trapped in the dermal 
layer.   Jackson and coworkers [30] reported log Poct/aq values for the related Cu(II) 
complexes of dioxo N5-donor ligands to be in the range -3.70 to -6.63 for the CuLH, CuL, 
CuLH-l and CuLH-2 species.   Nomkoko and coworkers [31] also reported log Poct/aq value of 
-1.25 at physiological pH 7.4 for the related dioxo N5-donor ligand.    
The partition coefficient GHK-Cu at pH 7.4 has been reported as -4.5 [32,33] and used to 
explain skin penetration typical for highly hydrophilic solutes [34,35].   Our Sar analogue.    
Sar-His-Lys is more lipophilic (a log Poct\aq = -3.02).   In order to increase their lipophilic 
properties, these small peptides could be transformed as palmitoyl derivatives, which exhibit 
a better delivery across skin [36].    
The results for all the Cu(II) complex species studied showed log Poct\aq values below zero, 
because the Cu(II) complexes of tripeptides are relatively hydrophilic.   The factors that 
contribute to the hydrophilicity of these complexes are the presence of coordinated water 
molecules, hydrogen bonding between charged groups in these species and the solvent 
molecules, the overall charge of the complex and  hydrogen bonding interactions between the 
carbonyl oxygen and bulk water molecules.   However, the present study indicates that topical 
administration of copper in the form of tripeptide may offer an effective alternative to 















5.3 MEMBRANE PERMEABILITY STUDIES (in vitro) 
5.3.1 Introduction 
Dermal absorption of chemicals has been tested in split-thickness skin and/or in epidermal 
sheets of various species including human, rat, rabbit, pig and mouse [37].   The potency of 
percutaneous absorption of chemical substances and drugs is characterised by the total 
dermally penetrated amount, the percentage of absorption of applied dose, the flux (J) and the 
permeability coefficient (Kp cm/h).   The relation between permeability coefficient and 
steady-state flux is given by the equation: 
                                                      Ci
JK p                                                                 (5.2)       
where, J is the amount of permeant crossing the membrane at a constant rate (mg/cm2. h); this 
occurs after a lag phase when the amount continues to increase [38,39], and Ci is the 
concentration of a metal such as Cu(II) in the donor phase at that point. The amount of 
permeant crossing the membrane J can be expressed as: 
 
                                                      tA
QJ
.
                                                                 (5.3) 
where Q (mg) is the quantity of Cu(II) transported through the membrane in time t (hrs), and 
A is the area of exposed membrane in cm2.     
The Franz diffusion cell technique is a common method used in permeation studies [39,40].   It is 
based on vertical diffusion between donor and acceptor phase.   In the Franz diffusion cell, a 
biological membrane is normally used to determine the diffusion of the metal ion.   However, the 
use of an industrial Franz diffusion cell with a biological membrane in permeation studies is 
impractical and difficult for several reasons.   Firstly, the setting up of the Franz cell is difficult 
because of its vertical design and it also requires large sample volumes.   Secondly, the 
efficiency of a biological membrane is dependent on the time they were obtained and on the 
conditions of conservation and treatment.   Lastly, the age, sex and weight of the membrane have 
to be taken into account during the studies.   However, these considerations for the biological 
membranes are unnecessary when using artificial membranes.    




In the present study, a horizontal Franz cell fitted with an artificial membrane, (Cerasome 9005), 
was used.   This membrane is a lipid solution which mimics human stratum corneum.    
Cerasome 9005 was purchased from Germany (Lipoid GmbH, Frigenstr.4, D-67065 
Ludwigshafen, 2008) and possessed the following characteristics: consistency (aqueous, 
transparent to opaque dispersion), colour (off-white), solid matter (10%), phosphorus (0.11%), 
pH (7.1) and mean particle size (200 nm) [40,41].    
 
                 
  Figure 5.12: Modified Franz cell apparatus using in this study. 
Where; 
1. Donor phase filled with 20ml of Cu(II) tripeptide complex. 
2. Receiver phase filled with blank solution (distilled/deionised water). 
3. The artificial membrane (0.085 g). 
4. Passive diffusion direction. 
5. Clamp. 
6. Stirrer bar. 
7. Magnetic stirrer. 
8. Burette stands with clamp. 
 
5.3.2 Experimental 
Figure 5.12 shows the details of a modified Franz diffusion cell used in this study for the 
permeability experiments.   The receiver cell was filled with 20 ml of distilled/deionised 
water.   Copper tripeptide solutions (0.005 M) were prepared in distilled/deionised water and 
20 ml samples at pH 7.0 were placed in the donor phase compartment.   The artificial 
membrane was prepared using a filter paper (Whatman, of 2.54 cm2 discs and thickness 




0.002cm) which was submerged in Cerasome 9005, dried for a few minutes at room 
temperature and then weighed.   The amount of lipid absorbed determined by mass 
difference, was 0.085 g.   The available diffusion area between cells was 0.709 cm2.   The 
contents of the cells were stirred by a magnetic stirrer.   The experiments were conducted 
over a period of 72 hours at room temperature.   During this period, both cells were covered 
so that the water could not evaporate and the experiments were conducted at room 
temperature.   Copper concentration (ppm) was determined using an Agilent 4100 Microwave 
Plasma-Atomic Emission Spectrometer (MP-AES).   The instrumental detection limit for 
copper at a wavelength of 324.75 nm was 0.2 ppb.   For analysis, samples were appropriately 
diluted using 5% HNO3 immediately prior to analysis.   Standard solutions of Cu(II) were 
prepared from certified standards (ULTRASPEC)  as described before [15,26,27].   
Measurements were done in triplicate, using the points from 24 to 72 hours.   Results are 
expressed as mean ± SE. 
 
5.3.3 Results and Discussion 
5.3.3.1 Franz cell 
The concentrations of Cu(II) tripeptide complexes at pH 7.0 as a function of time (h) are 
plotted in Figure 5.13 and shown in Table 5.1.     
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It can be seen that the diffusion of the copper complexes is slow for the first 6 hours of the 
experiment.   This is followed by a further phase of rapid diffusion, called the steady state, 
from 6 to 72 hours.  
The reason for the observed induction period was attributed to the development of 
equilibrium between the donor phase and the membrane as a result of the complex diffusing 
through it [42,43].   Thereafter, there was a steady state flux of copper into the receiver phase.   
This is shown by the straight line from 24 to 72 hours as shown in Figure 5.13.   From the 
slope of the curve the steady state flux permeability coefficient can be calculated (Table 5.3). 
 
Table 5.2: Cu(II) concentration (ppm) in receiver phase of Franz cell at pH 7.0 as a function 
of time (h). 
Time 
(h) 
SHK SKH SHH SKK SGH Cl- 
0 0 0 0 0 0 0 
2 
 
3.5 ± 0.1 2.4 ± 0.1 2.8 ± 0.1 0.5 ± 0.1 1.3 ± 0.1 0.08 ± 0.1 
4 
 
5.5 ± 0.1 4.1 ± 0.1 4.9 ± 0.1 1.1 ± 0.1 2.2 ± 0.1 0.24 ± 0.1 
6 
 
6.5 ± 0.1 5.8 ± 0.1 6.0 ± 0.1 1.7 ± 0.1 3.0 ± 0.1 0.44 ± 0.1 
24 
 
15.0 ± 0.1 17.8 ± 0.1 19.7 ± 0.1 7.7 ± 0.1 10.8 ± 0.1 5.68 ± 0.1 
30 
 
18.5 ± 0.1 19.6 ± 0.1 22.4 ± 0.1 8.5 ± 0.1 13.7 ± 0.1 6.52 ± 0.1 
48 
 
25.0 ± 0.1 32.1 ± 0.1 34.4 ± 0.1 12.9 ± 0.1 18.9 ± 0.1 10.12 ± 0.1 
54 
 
28.5 ± 0.1 35.0 ± 0.1 41.4 ± 0.1 14.2 ± 0.1 20.0 ± 0.1 10.88 ± 0.1 
72 
 














Table 5.3: Flux of diffusion J and permeability coefficient Kp of copper tripeptide complexes 
through Cerasome 9005 membrane at pH 7.0. 
Complexes J mg\cm2h Kp cm\h 
Cu-SHK 0.009 ± 0.01 0.049 ± 0.01 
 
Cu-SKH 0.013 ± 0.01 0.047  ± 0.01 
 
Cu-SHH 0.012 ± 0.01 0.041  ± 0.01 
 
Cu-SKK 0.005 ± 0.01 0.038  ± 0.01 
 
Cu-SGH 0.007 ± 0.01 0.061 ± 0.01 
        CuCl2.2H2O 
*pH 4.20 
           0.004 ± 0.05               0.028  ± 0.07 
 
 
5.3.3.2 Flux (J) and permeability coefficient (Kp) calculations 
The flux was calculated from the slope of the linear portion of the plot of cumulative amount of 
Cu(II) penetrated per square centimetre through Cerasome 9005 membrane as a function of time 
(Figure 5.13).   The permeability coefficient Kp was calculated using Equation 5.2.   The flux 
values and permeability coefficients are presented in Table 5.3 and are shown graphically in 
Figures 5.14 and 5.15, respectively. 
 
 
Figure 5.14: Effect of different tripeptides on the flux of copper through Cerasome 9005 




















Figure 5.15: Influence of tripeptides on the permeability of copper complexes through 
Cerasome 9005 membrane at pH 7.0. 
 
The results show the influence of different tripeptide systems on the flux and the permeability 
coefficients of copper ions through the Cerasome 9005 as a membrane.   These results 
suggest that the complexation of Cu(II) ions with tripeptides greatly increases the permeation 
rate of copper ions, as Kp values for complexed species are significantly higher than the one 
for CuCl2.   The following order of permeability coefficient Cu-Sar-Gly-His > Cu-Sar-His-
Lys > Cu-Sar-Lys-His > Cu-Sar-His-His > Cu-Sar-Lys-Lys > Cu-Cl- was obtained. 
In previous studies, the permeabilities of the Cu(II) complexes with amino acids were closely 
related to their stabilities, as described by log K [44].   The permeability coefficients (Kp) and 
stability constants (log K) for copper complexes with alanine, glycine, valine, and lysine were 
similar.   However, both the Kp and the log K values for the copper histidine complex were 
higher than those evaluated for the other amino acid complexes due to its higher molecular 
weight [45].   This effect of MW on the flux of copper complexes was observed by Potts et al [42].       
Jurij et al. [46] determined the skin permeability coefficient Kp for Gly-L-His-L-Lys cuprate 
diacetate in vitro and found it to be 2.43 ± 0.51x10-4 cm/h using an isolated stratum corneum 
(model membrane).   He predicted, therefore, that copper as a tripeptide complex will be 
delivered in potentially therapeutically effective amounts for inflammatory disease.   The copper 





















investigations of the influence of complexing agents on the skin migration rate of copper ions 
have yielded evidence for their hampering role in this process [47]. 
 
5.3.3.3 Relationship between logarithm of permeability coefficient (Log Kp) and molecular 
weight (MW) of copper complexes 
Table 5.4 is a summary of Cu(II) speciation at pH 7.4, MW and the permeation coefficient of the 
copper (II) tripeptide complexes.  
 
Table 5.4: The permeability coefficients values of Cu(II) speciation in the presence of 
different tripeptides at pH 7.4.  
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Figure 5.16: Logarithm of permeability coefficient plotted against molecular weight of Cu(II) 
tripeptide complexes. 
 
In calculating the molecular weight, it is assumed that the metal is square planar with free 
coordination sites occupied by water.   This is necessary because the water of coordination is 
generally not specified in the stoichiometry but needs to be inferred from the structure.   The 
coefficient of correlation obtained from Figure 5.16 was R2 = 0.7306 ± 0.005, which is the 















of the variability can be explained by MW of the Cu(II) complexes.   If Cu-Sar-Lys-Lys include 
in the regression analysis a correlation coefficient of R2 = 0.477 ± 0.01 was obtained.   This 
means that the His residue has a big effect on the permeability of the complex. 
 
5.3.3.4 Relationship between permeability coefficient (Log Kp), octanol/water partition 
coefficient (Log Poct\aq) and molecular weight (MW) of copper complexes 
The effect of molecular weight (MW) of a complex on its flux was also observed and reported by 
Potts et al [42].    This effect can be obtained quantitatively from their equation based on two 
physicochemical properties of octanol-water partition coefficient log Poct\aq and molecular weight 
MW of complex and is given by the linear relationship [48].   The following equation was used 
to predict skin permeability [49] : 
 
Log Kp = Log (D0/h) + f Log Poct\aq – β’ MW                      (5.4) 
where, Kp= the permeability coefficient; D0= the diffusivity of hypothetical molecule having zero 
molecular weight; h = the membrane thickness; f = constant which accounts for the difference 
between the partitioning domain presented by octanol and that presented by the membrane lipids; 
Poct\aq = the octanol/water partition coefficient; MW = molecular weight, β’ = a constant which 
includes a conversion factor for the substitution of molecular weight for molecular volume.   The 
Cerasome 9005 membrane thickness was (h=0.002cm). 
In this study, was used this model to examine the permeability data through a Cerasome 9005 
membrane, although the model was initially used to describe skin permeabilities of non-ionic 
drugs dissolved in water.   Multiple linear regression analysis of log Kp upon log Poct\aq and MW 
was used to obtain values for β’, log (D0/h) and f. 
 
Table 5.5: The permeability coefficients and the partition coefficient values of Cu(II) 
speciation in the presence of different tripeptides at pH 7.4.  
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The coefficient of correlation obtained from relationship between octanol/water partition 
coefficients (log Poct\aq) and molecular weights of the bases (MW) were found not to correlate 
with permeability coefficients (log Kp) is R2 = 0.44 ± 0.01, which is far from 1, demonstrating 
that there is no correlation between permeability coefficient, partition coefficient and molecular 
weights of all complexes.  
   
5.3.4 Conclusion 
The presented results suggest that the complexation of Cu(II) ions by the different tripeptides 
greatly influences the diffusion of copper ions across the membrane because different flux and 
permeability coefficients values were obtained for the different copper (II) tripeptide complex 
species  studied.   The Kp value for the Cu-Sar-Lys-Lys was lower than the other copper 
tripeptide complexes, because histidine is not present in this ligand.   When comparing the 
permeation coefficient of copper tripeptide complexes of Cu-Sar-Gly-His and Cu-Sar-His-His, 
there was a decrease in Kp and this was attributed to the higher molecular weight of Cu-Sar-His-
His.   The obtained results show that the permeability rate of tripeptide Cu(II) complexes through 
Cerasome 9005 membrane depend on which species predominate in solution at pH 7.0.   
In addition, copper complexes with tripeptides penetrate through the model membrane as copper 
complexes.   In this study, however, the transport of copper through a model membrane with 
tripeptides greatly increased the permeation rate of copper ions since Kp values for complex 
species were significantly higher than those for simple Cu(II) ions.   Furthermore, it can be 
concluded from the obtained results that no correlation was found between molecular weight, 
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Copper complexes have been found to exhibit  lower toxicity and higher anti-inflammatory 
activity as compared to their parent compounds or ligands [1].   The present study focuses on 
the design of new drugs that will alleviate the inflammation associated with rheumatoid 
arthritis.   There are two ways of increasing the available pool of low molecular weight Cu(II) 
species in vivo, endogenously or exogenously.   Endogenous increase means that the drug 
releases Cu(II) from natural stores ie serum albumin.   Exogenous means that Cu(II) is 
administered orally, dermally or by injection.   Of these three methods we prefer dermal 
absorption as offering one obvious advantage of being less painful and hence tolerable to the 
patient [2].   For this reason the drugs were designed so that they could be administered 
dermally and be selective for Cu(II) so that they do not affect the speciation of other metal 
ions in blood plasma.    
 
The first step in this investigating was to design new ligands.   In normal blood plasma, 
Cu(II) is transported complexed to the N-terminus of serum albumin.   The binding site is 
Asp-Ala-His.    For this reason, histidine containing tripeptides were chosen for evaluation.   
In addition N-methyl glycine was used as this is commercially available, is less susceptible to 
metabolism in vivo, and it may increase the lipophilicity of the complex, without 
compromising its Cu(II) binding.   The ligands chosen were sarcosyl-L-histidyl-L-lysine 
(SHK), sarcosyl-L-lysyl-L-histidine (SKH), sarcosyl-L-histidyl-L-histidine (SHH), sarcosyl-
L-lysyl-L-lysine (SKK) and sarcosyl-L-glycyl-L-histidine (SGH).   Having decided on the 
ligands, the next step was to measure their Cu(II)  binding and selectivity using glass 
electrode potentiometry.   The equilibrium constants of H+, Cu(II), Ni(II), and Zn(II) at 25°C 
and in 0.15 M Na+(Cl-) were measured.   The Cu(II) tripeptide species showed a significantly 
different coordination behaviour at physiological pH.   At this pH, the Cu(II) tripeptide 
complexes showed formation of CuL 99% (SHK); CuLH-1 98%(SKH); CuL 25%, CuLH-l 
73% (SHH); CuL 77%, CuLH-l 21% (SKK) and CuLH-2 73% (SGH).   Moreover, the 
tripeptides with histidine produced the strongest ligand field and the most stable CuL species 
was with Sar-His-Lys (SHK).   The results presented in this study showed that the metal ion 
complexation strongly depends on the position of histidine in the amino acid sequence of the 
tripeptide molecules.   The methyl group also had an inductive effect, making the Sar 
tripeptides more basic than Gly tripeptides.   Similarly the Cu(II) complexes of Sar-His-Lys 
and Sar-Gly-His were more stable than their Gly analogues. 




The formation equilibria for Ca(II), Ni(II) and Zn(II) show that these metal ions also form 
relatively stable complexes with the tripeptides, although their stability is lower than that of 
Cu(II).   The selectivity of the ligands for Cu(II) at physiological pH was Cu(II)/Ca(II) > 
Cu(II)/Zn(II) > Cu(II)/Ni(II).   This then suggests that the tripeptide species are likely to 
complex Cu(II) in vivo, despite competition from Ca(II), Ni(II) and Zn(II).   However, high 
concentrations of Ca(II) and Zn(II) in vivo could upset the favourable selectivity for Cu(II). 
 
In order to evaluate the Cu(II) mobilising ability of the ligands an in vivo speciation model of 
the blood plasma, ECCLES, was used.   The simulations showed that, because the 
concentration of Ca(II) and Zn(II) in blood plasma is much higher than Cu(II), even though 
the Cu(II) complexes are more stable, these metal ions do affect the Cu(II) mobilisation.   It 
was shown that the Cu(II) mobilising ability of the ligands was in the order Sar-Lys-His > 
Sar-Gly-His ≈ Sar-His-His ≈ Sar-His-Lys > Sar-Lys-Lys.   At a concentration of 10-5 to 10-4 
mol dm-3 the ligands were able to cause a 10 fold increase in the concentration of low 
molecular weight Cu(II) complexes.   However, Sar-His-Lys and Sar-His-His also affected 
the speciation of Ca(II).  
 
Having established that these ligands are able to complex Cu(II) in vivo and in order to 
understand the difference in stability of the different Cu(II) complexes their chemical 
structures were determined.   This was done using Uv-Vis, 1H NMR, ESI-MS spectroscopy 
as well as molecular mechanics calculations.   It was also important to know their structure as 
this would determine their physical properties and hence bioavailability.   The colours of 
Cu(II) tripeptide species at different pHs are shown in Figure 6.1.   A visual check can 
distinguish between species as colours vary from light blue to purple.   This change in colour 
indicates a change in coordination as different species are formed e.g. the formation of the 4N 
species, CuLH-2 from the 3N species, CuLH-1.   The potentiometric and spectroscopic results 
obtained for the tripeptide containing His at position II reported the formation of CuLH-1 as a 
3N complex and a light blue colour.   The copper was ligated to Sar-His-Lys via three bonds 
in the equatorial plane.   The fourth equatorial position could be a water molecule.   When the 
His was at position III a λmax of 520 nm (purple colour) was obtained indicating the formation 
of 4N [-NH, 2N-, Nim] species for CuLH-2.   The Uv-Vis spectra of copper binding with the 
tripeptide containing His simultaneously at the second and third positions Sar-His-His 
showed patterns similar to those of the complexes with Sar-His-Lys and Sar-Lys-His.   




Sar-Lys-Lys does not have His and therefore, both amide groups can be in the equatorial 
plane and deprotonated to give the CuLH-2 species.   This is the same  as Gly-Gly-Gly with 
3N [-NH,2N‒,O(COO-)] [3,4].  
 
Figure 6.1: Cu(II) tripeptide  showing the colour of the CuLH-1 3N and CuLH-2 4N species. 
   
The 1H NMR studies showed that the active binding sites for tripeptide are the imidazole 
nitrogen, the amide nitrogen and the terminal -NH groups.   The imidazole nitrogen was 










chemical shifts of Cu(II) complexes of Sar-His-Lys, Sar-His-His and Sar-Gly-His, the 
imidazole ring of the histidine residue, with its two N3 and N1 nitrogen atoms, were shown to 
be a good metal-binding site in the reaction of histidine-containing peptides with Cu(II).   The 
ԑ-amino group of lysine were relatively unaffected by copper addition, indicating that the 
lysine side chain does not coordinate to the Cu(II) [5].    
Attempts to confirm the speciation of the Cu(II) complexes using ESI-MS were not that 
successful.   The different species differ by one or two protons.   The addition or the loss of a 
proton are very quick processes, which occurred during the electro-spray ionization.   For this 
reason, while it was possible to see the Cu(II) complexation, it was not possible to get the 
accurate stoichiometry.  
While it is possible to suggest the structure of different species from potentiometry and 
spectroscopy, it is not clear that these structures are physically feasible.   For this reason, 
molecular mechanics (MM) modelling was used to calculate the strain energies (internal 
energy) of different possible copper complex geometries under biological conditions.   This 
can guide the choice of peptides for the sequestration of copper such as sensing the presence 
of copper with the highest sensitivity, forming the most stable copper complex or removing 
the greatest amount of copper.   At physiological pH, all the ligands formed square planar 
complexes with low stain energy.   These results were in agreement with the potentiometric 
and spectroscopy studies. 
 
One of the objectives of the study was to develop Cu(II) complexes that could be 
administered trans-dermally.   Traditionally, octanol/water partition coefficients are used as 
an indication of transdermal absorption.   Different species can have different partition 
coefficients and so we measured these as a function of pH.   The results showed that all the 
Cu(II) complex species studied had log Poct\aq valves below zero indicating that the 
complexes were relatively hydrophilic.   Deprotonation of the ligand as well as N-methyl 
substituent on the terminal amine improved the lipophilicity.   One of the reasons for using 
N-methyl substitution was to improve lipophilicity and these results confirm that this was 
achieved. 
Although partition coefficients are traditionally used as a proxy for dermal absorption, these 
studies have used organic drugs not metal complexes.   In order to confirm that partition 
coefficients can be used in this way, skin permeability was measured using an artificial 




membrane.   The permeability coefficient Kp for the Cu(II) tripeptide complexes was in the 
order :    Cu-Sar-Gly-His > Cu-Sar-His-Lys > Cu-Sar-Lys-His > Cu-Sar-His-His > Cu-Sar-
Lys-Lys > Cu-Cl-.   Sar-Gly-His increased the permeability of Cu(II) 2 fold.   However, from 
the results obtained, there was no correlation between partition coefficient and permeability 
coefficient.   Other researchers have proposed that multiple linear regressions should be used 
where molecular weight is included in the regression.   From our results a correlation was 
only found between Kp and molecular weight.   This indicates that care must be exercised 
when using partition coefficients as a proxy for tissue permeability.   
Sar-Lys-His and Sar-Gly-His have a higher mobilising capacity than all the other tripeptides.   
The results obtained from this study were compared with the terminal amino acid sequence of 
serum albumin, which is the endogenous copper transport protein.   Our study demonstrated 
that the Cu(II)-binding affinity of these ligands are comparable with those of glycyl-glycyl- 
L-histidine (Gly-Gly-His) and L-aspartyl-L-alanyl- L-histidine N-methyl amide (Asp-Ala-
His-NHMe).   The present study has contributed to the understanding of some aspects and 
problems involved in the development of copper complexes agents for the alleviation of 
inflammation associated with rheumatoid arthritis (RA).   
 
 In the present study, the design of these ligands was based on the structure of human serum 
albumin (HSA).   At the same time the tripeptides with histidine demonstrated that the metal 
ion complexation strongly depends on the position of histidine in the tripeptide molecules.   
Besides introducing new ideas that can be successfully applied in solution chemistry, the 
study has clearly outlined the approach that could be followed in future studies for 
investigating new anti-inflammatory drugs for RA.   Lysine was used in this study, but our 
results show that its side chain does not coordinate to the Cu(II).   Thus it would be better to 
use a more lipophilic amino acid in future.   Furthermore, it would be interesting to 
investigate the copper bio-distribution in animal experiments using 64Cu(II) as a radiotracer.   
In addition, in vivo experiments using an animal model of inflammation, like Carrageenan 
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